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 ABSTRACT
 
 
 Primary hepatocytes treated with non-esterified polyunsaturated fatty acids have been 
used as a model for describing the inhibitory effects of dietary polyunsaturated fats on lipogenic 
gene expression. This model resembles starvation or uncontrolled diabetes but not dietary fat 
ingestion, which is delivered to liver via chylomicron remnants. Chylomicron remnants enriched 
with polyunsaturated fatty acids stimulate a unique pattern of intracellular signaling. These 
remnants enhance p38 mitogen activated protein kinase (MAPK) activity but do not inhibit 
insulin signaling or induce extracellular-signal related kinase (ERK) or AMP-activated protein 
kinase (AMPK) activation as do non-esterified polyunsaturated fatty acids. Polyunsaturated fatty 
acids-enriched remnants and non-esterified polyunsaturated fatty acids both inhibit the rate of 
fatty acid synthesis and the expression of the lipogenic genes, particularly those regulated by 
sterol response element binding protein-1c (SREBP-1c). Saturated fatty acid-enriched remnants 
fail to inhibit the lipogenic genes indicating that the inhibitory action of dietary polyunsaturated 
fats involves regulatory mechanisms in liver.  In contrast, polyunsaturated fatty acids-enriched 
remnants fail to inhibit malic enzyme, glucokinase, L-pyruvate kinase, and cytochrome P450-7α 
(Cyp-7α) expression despite their inhibition by non-esterified fatty acids. These genes are 
regulated independently of SREBP-1c.  Therefore, non-esterified polyunsaturated fatty acids do 
not accurately model all aspects of regulation of hepatic metabolism by dietary fat. 
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CHAPTER I. 
 
I. SIGNIFICANCE OF POLYUNSATURATED FATTY ACIDS IN HUMAN 
 HEALTH 
 
As the incidence of heart disease, obesity, and type 2 diabetes increases in the United 
States, diet as a causative and preventative factor has gained attention. Just as it was once 
necessary to elucidate the obligatory vitamins and macronutrients needed for the body, it is now 
necessary to determine the proportions and types of fat, cholesterol, and carbohydrates necessary 
for proper health. Specifically, insight into nutritional control of metabolism and gene expression 
is quite important if these diseases are to be better understood and for clinical interventions to be 
improved. 
Where these diseases intersect is in the disregulation of metabolism such that insulin 
signaling and lipid homeostasis are disrupted. It is known that dietary polyunsaturated fatty acids 
are able to regulate both insulin signaling and their own metabolism (1-3). Therefore it is 
increasingly important to understand the action of dietary polyunsaturated fatty acids on 
metabolic processes.  
 
II. POLYUNSATURATED FATTY ACID BIOCHEMISTRY 
 
 Fatty acids with two or more double bonds are known as polyunsaturated fatty acids. 
There are two main families of polyunsaturated fatty acids, the n-3 and n-6 polyunsaturated fatty 
acids, which are named by the position of the distal double bond relative to the terminal methyl 
end of the fatty acid (these fatty acids are sometimes also classified in popular literature as 
omega-3 and omega-6 polyunsaturated fatty acids).  Mammals are unable to synthesize the 18-
carbon precursors of all the necessary n-3 and n-6 polyunsaturated fatty acids, and n-3 and n-6 
polyunsaturated fatty acids cannot be inter-converted within the cell. Therefore, the 18-carbon n-
3 and n-6 fatty acids are termed “essential fatty acids” that must be obtained from the diet to 
support normal metabolism. Linoleic acid (n-6) and linolenic acid (n-3) are the dietary sources of 
essential polyunsaturated fatty acids. The loss of these fatty acids in the diet results in essential 
fatty acid deficiency, which results in a loss of integrity of the skin and cell membranes, and an 
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inability to synthesize eicosanoids (4). In western diets, the most abundant sources of n-6 
polyunsaturated fatty acid are safflower, sunflower, and soybean oils. The most abundant sources 
of n-3 polyunsaturated fatty acid are canola and linseed oil, and salmon (5, 6). However, both n-3 
and n-6 polyunsaturated fatty acids are present in a variety of foods, including other fish, nuts, 
and some meat (7, 8). 
 In the endoplasmic reticulum, linoleic and linolenic acid are further metabolized into 
long-chain highly unsaturated fatty acids to provide substrate fatty acids for the formation 
eicosanoids, intracellular signaling molecules, structural components of the cell membrane, and 
for β-oxidation. Linoleic and linolenic acids undergo sequential desaturation and elongation 
reactions to form arachidonic and eicosapentaenoic acid, respectively. The conversion of linoleic 
and linolenic acids to their long-chain highly unsaturated fatty acids involves the fatty acid 
elongases (ELOVL5 and ELOVL2) and desaturases (delta-6- and delta-5-desaturases)(9).  Delta-
6-desaturase is the rate-limiting enzyme in the metabolism of n-3 and n-6 polyunsaturated fatty 
acids to their highly unsaturated fatty acid products (Figure 1)(10). 
 
FIGURE 1. 
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 Arachidonic and eicosapentaenoic acids are the 20-carbon precursors of eicosanoids, 
which are signaling molecules derived through the oxidation of 20-carbon precursor fatty acids. 
Eicosanoids mediate inflammation in response to cell stress, cytokines, or growth factors. 
Biosynthesis begins when arachidonic and eicosapentaenoic acids, which are stored in the 
cytosolic leaflet through their esterification to membrane phospholipids and glycerides, are 
mobilized by the action of phospholipase A2 to form free arachidonic and eicosapentaenoic acids 
(11).  Arachidonic acid is converted to prostaglandins and thromboxanes by cyclooxygenases, 
and to leukotrienes by lipoxygenases; these enzymes form the pro-inflammatory eicosanoids. 
Eicosapentaenoic acid will be converted by cyclooxygenases to anti-inflammatory eicosanoids 
(9). This is a major difference in the downstream action of the n-3 and n-6 polyunsaturated fatty 
acids. 
 Aside from their roles in eicosanoid metabolism, polyunsaturated fatty acids also mediate 
cell membrane signaling pathways. When they are esterified to the two-carbon of phospholipids 
within the cell membrane, they participate in signal transduction pathways involving 
diacylglycerol.  Docosahexaenoic acid, an n-3 derivative of linolenic acid, binds to the G 
protein-coupled receptor (GPCR) rhodopsion in the retina. There, it is necessary for maintaining 
the responsiveness of the GPCR to light (12, 13). Eicosanoid derivatives of arachidonic acid 
have also been shown to modulate other GPCRs involved in host defense and inflammatory 
responses (14).   
 n-3 and n-6 polyunsaturated fatty acids are also necessary for maintaining cell membrane 
function. As the polyunsaturated fatty acid content of the cell membrane increases, so does its 
fluidity (due to the increase in “kinks” formed by the multiple double bonds of n-3 and n-6 
polyunsaturated fatty acids). In skin, linoleic acid (n-3) is necessary for skin structure and 
function because it is a component of ceramides (15). In neurons, DHA (n-6) is necessary for 
supporting cell survival through its binding to membrane phosphotidylserine (16). 
 
III. LIPOGENESIS 
 
 Lipogenesis is the process by which simple sugars such as glucose are converted to fatty 
acids, which are subsequently esterified with glycerol to form triacylglycerols. When excess 
energy is ingested beyond the body's immediate energy needs, the excess energy is converted 
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into triacylglycerol through the process of lipogenesis. Conversely, when insufficient calories are 
ingested, this triacylglycerol is oxidized to make up for the energy deficit. Lipogenesis occurs 
primarily in liver (where the triacylglycerol is exported to peripheral tissues in VLDL particles), 
adipose (the major storage site of triacylglycerol), and lactating mammary glands (where 
triacylglycerol is secreted in milk)(reviewed in 17, 18).  
 The formation of triacylglycerol requires long-chain fatty acids either obtained from the 
diet, or synthesized from acetyl-coenzyme A (acetyl-CoA) through a concerted set of reactions 
that include glycolysis, the citric acid cycle, the pentose phosphate pathway, and fatty acid 
synthesis. These reactions collectively provide the carbon and reducing equivalents necessary to 
produce fatty acids that will be esterified to glycerol to form triacylglycerol (Figure 2)(19). 
 The synthesis of fatty acids by fatty acid synthase (FAS) requires acetyl-CoA, malonyl-
CoA, and NADPH. Acetyl-CoA is provided from the reactions of glycolysis (which provides 
pyruvate for the citric acid cycle) and the citric acid cycle (which exports citrate from the 
mitochondria to the cytoplasm). ATP-citrate lyase (ATP-CL) then catalyzes the conversion of 
citrate to acetyl-coA and oxaloacetate. The reactions of the pentose phosphate pathway provide 
NADPH reducing equivalents for the subsequent reactions of fatty acid synthesis. Since the 
enzymes in these pathways work in concert to provide either substrate or reducing equivalents, 
these enzymes are termed the lipogenic family of enzymes. Members of the lipogenic enzyme 
family include malic enzyme (ME), glucose-6-phosphate dehydrogenase (G6PD), acetyl-CoA 
carboxylase (ACC), ATP-citrate lyase (ATP-CL), and fatty acid synthase (FAS)(10).  
 Acetyl-CoA carboxylase (ACC) is the rate-limiting enzyme in fatty acid synthesis, and it 
catalyzes the synthesis of malonyl-coA from acetyl-CoA. ACC is allosterically inhibited by 
long-chain fatty acids and by AMPK-mediated phosphorylation when cellular AMP levels are 
high. Malonyl-CoA is the C2 donor in the de novo synthesis of fatty acids, and it is also an 
inhibitor of the carnitine-palmitoyl shuttle system for fatty acid oxidation in the mitochondria 
(20, 21). 
 All subsequent reactions of fatty acid synthesis are carried out by the 4 enzymatic 
activities of FAS. These include: β-keto-ACP synthase, β-keto-ACP reductase, 3-OH acyl-ACP 
dehydratase and enoyl-CoA reductase. The reduction reactions require the NADPH (20). The 
primary fatty acid synthesized by FAS is palmitate, which is released from the enzyme to 
undergo additional elongation and/or desaturation reaction to provide other fatty acids. 
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Alternatively, palmitate can become the substrate for triacylglycerol synthesis. 
 
FIGURE 2. 
 
 
IV.  β-OXIDATION 
 
 Dietary fat is predominantly triacylglycerol. The fatty acids comprising the 
triacylglycerol molecule are saturated, monounsaturated, and polyunsaturated. These fatty acids 
provide a major source of energy through their own β-oxidation. Fatty acids stored as 
triacylglycerols (primarily within adipose tissue) are also substrates for β-oxidation. In response 
to energy deprivation, the fatty acids of stored triacylglycerols are mobilized for use by the 
peripheral tissues.  
 In adipose tissue, a stimulus for the mobilization of stored triacylglycerol is glucagon or 
epinephrine. Upon binding to cell-surface receptors, these hormones stimulate the activation of 
adenylate cyclase, resulting in an increase intracellular cAMP and the activation of PKA (22). 
PKA then phosphorylates and activates hormone sensitive lipase (HSL), which will then 
hydrolyze fatty acids from triacylglycerols. This stimulation is inhibited by insulin, which alerts 
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the body that energy in the form of glucose is available for peripheral tissues to use rather than 
stored fatty acids. The complete hydrolysis of fatty acids from the glycerol backbone also 
requires the non-inducible enzymes diacylglycerol lipase and monoacylglycerol lipase (23-26). 
Once free fatty acids are hydrolyzed from the glycerol backbone, they are able to diffuse out of 
adipocytes into the blood, where they become bound to albumin. Fatty acids bound to albumin 
are then transported to tissues for uptake and β-oxidation (23-26).  
 For β-oxidation in peripheral tissues, these free fatty acids enter the cell and must be 
activated in the cytoplasm to form a fatty acyl-CoA thioesters, catalyzed by acyl-CoA synthetase 
(27). The transport of fatty acyl-CoA into the mitochondria is accomplished by an acyl-carnitine 
intermediate that is generated by carnitine palmitoyltransferase I (CPT I) on the outer 
mitochondrial membrane (28). This acyl-carnitine is then transported into the mitochondria 
where CPT II catalyzes the regeneration of the fatty acyl-CoA molecule. The fatty acyl-CoA 
molecule is the substrate for β-oxidation (Figure 3A)(23-26).  
 
FIGURE 3A. 
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 β-oxidation occurs through the sequential removal of 2-carbon units through oxidation at 
the β-carbon position of the fatty acyl-CoA. β-oxidation reactions proceed through the actions of 
acyl-coA dehdyrogenase, enoyl-CoA hydratases, L-3-hydroxyacyl-CoA dehydrogenases, and 
thiolases (25, 29). Each round of β-oxidation produces one mole of NADH, one mole of FADH2 
and one mole of acetyl-CoA. The acetyl-CoA is further metabolized by the citric acid cycle. 
Acetyl-CoA can also be diverted to synthesize ketone bodies (β-hydroxybutyrate and 
acetoacetate), which are exported to tissues such as brain where β-oxidation does not occur. The 
NADH and FADH2 generated during β-oxidation and by the citric acid cycle then enter the 
respiratory pathway for the production of ATP (Figure 3B)(23-25). 
 
FIGURE 3B. 
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V. DIETARY POLYUNSATURATED FAT AS A REGULATOR OF LIPOGENESIS 
 
 The discovery that fatty acids can inhibit lipogenesis and lipogenic enzyme activity (and 
therefore modulate energy homeostasis) is essential to understanding how changes in dietary fat 
consumption may mediate a decrease in cardiovascular disease. It is well established that in 
contrast to the stimulatory effect of dietary carbohydrate, the inhibitory effect of polyunsaturated 
fat on lipogenesis and lipogenic enzyme activity is due specifically to the inclusion of 
polyunsaturated fat to the diet (30-32). 
 When rats are switched from a high-carbohydrate fat-free diet to a diet containing 
polyunsaturated fat, hepatic lipogenesis and the lipogenic enzyme activity are inhibited (33). 
Regardless of whether the rats have been starved and then re-fed a high-carbohydrate diet 
supplemented with polyunsaturated fat, or whether the rats receive a single gavage of 
polyunsaturated fat, lipogenesis and lipogenic enzyme activity are inhibited (34, 35).  In support 
of this data, when the carbohydrate content of a diet is held constant, but either polyunsaturated 
or saturated fat is added to the diet only the polyunsaturated fat inhibits lipogenesis and lipogenic 
enzyme activity (33, 36). Neither monounsaturated nor saturated fatty acids inhibit lipogenic 
enzyme activity in these diets (33, 34, 36). The specific inhibitory effects of dietary 
polyunsaturated fat are not due to essential fatty acid deficiency; in rats fed a diet adequate in 
essential fatty acids but supplemented with polyunsaturated fat, lipogenesis and lipogenic 
enzyme activity in further inhibited (33).   
 The specific inhibition of lipogenesis by polyunsaturated fatty acids but not saturated fats 
suggest that prostanoids may mediate this effect. However, both n-3 and n-6 polyunsaturated 
fatty acids inhibit lipogenesis (but give rise to different prostanoid products), and inhibiting the 
metabolism of dietary linoleic acid does not abolish the effect of polyunsaturated fatty acid on 
lipogenesis (37, 38). Therefore, the mechanism by which polyunsaturated fatty acids inhibit 
lipogenesis does not involve their metabolism to prostanoid products. 
 The molecular basis for the inhibitory effects of polyunsaturated fatty acids on 
lipogenesis and lipogenic enzyme activity is still incomplete. In order to address this molecular 
mechanism, isolated hepatocytes in culture have been used to study the inhibitory effects of fatty 
acids on lipogenesis and lipogenic enzyme activity. In primary rat hepatocytes, the addition of 
non-esterified fatty acids inhibits lipogenesis and the activity of ACC, FAS, ATP-CL, G6PD, 
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and ME (28, 39-41). Adding polyunsaturated fatty acids in primary hepatocytes mimics the 
effects of adding polyunsaturated fat to the diet of rats; n-3 and n-6 polyunsaturated fatty acids 
inhibit lipogenesis and lipogenic enzyme activity; saturated fatty acids do not accomplish this 
inhibition (with the exception of ACC, which is inhibited at low concentrations by palmitate; 
however, palmitate become cytotoxic at concentrations above 250 mM, suggesting that its effect 
may be due to this toxicity rather than a specific effect of fatty acid on enzyme activity)(33, 42).  
 Due to this strong correlation between experiments in intact rat and primary hepatocytes, 
primary hepatocytes have been utilized to address a central question in this field: primarily, what 
are the specific intracellular mechanisms that mediate the inhibitory effect of polyunsaturated fat 
on lipogenesis and lipogenic enzyme activity.  
 
a. TRANSCRIPTIONAL REGULATION BY POLYUNSATURATED FAT 
 
 As described above, polyunsaturated fatty acid, added to either hepatocytes in culture or 
to the diet of rats, is inhibitory to hepatic lipogenesis and lipogenic enzyme activity. The 
activities of ACC, FAS, ATP-CL, ME, and G6PD are coordinately regulated so that glucose is 
converted to palmitate only when dietary energy is high, and conversely, that fatty acids are 
funneled towards β-oxidation when dietary energy is low. This coordinate regulation of substrate 
(glucose) to product (fatty acid) is accomplished by changing the capacity of the lipogenic suite 
of enzymes.  This occurs through two mechanisms: 1) short-term changes in flux are 
accomplished in minutes through the inhibition of enzyme catalytic activity through 
phosphorylation and dephosphorylation or through the binding of allosteric inhibitors, and 2) 
long-term changes in flux are accomplished in hours by changing mRNA and protein synthesis 
of the key lipogenic enzymes.  
  Short-term regulation is only observed in ACC; this enzyme is inhibited by 
phosphorylation and also by the presence of long-chain fatty acyl-CoA. ACC is stimulated by the 
presence of citrate. These short-term controls enable flux through the fatty acid synthetic 
pathway (the pace of which is controlled by ACC) to change immediately upon the availability 
of acetyl-CoA substrate, or to be inhibited by product feedback (long-chain fatty acyl-CoA).  For 
the rest of the lipogenic enzymes, long-term changes in enzyme activity correspond to changes in 
the amount of the enzyme present in the cell. 
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 Polyunsaturated fatty acids cause large inhibitions in the rate of transcription of the 
lipogenic enzymes, thereby inhibiting both the amount of mRNA and protein synthesis in the 
liver, intestine, pancreas, and adipose tissue (43, 44). These nuclear effects occur within hours of 
feeding a diet rich in polyunsaturated fatty acid (43, 44). These transcriptional changes affect the 
amount of ATP-CL, FAS, ACC, and ME (45). These transcriptional mechanisms involve either 
the nuclear receptors LXR and PPAR-α, or the transcription factors SREBP-1c and ChREBP 
(46). The transcriptional mechanisms by which polyunsaturated fatty acids inhibit flux through 
the lipogenic pathway will be the focus of the rest of section.  
 In contrast to the transcriptional changes in other lipogenic genes, polyunsaturated fat 
does not inhibit G6PD at the transcriptional level. Instead, the level of G6PD mRNA is inhibited 
by changes in the processing of the pre-mRNA transcript (47). This posttranscriptional 
regulation will be discussed below.  
 
i. LIVER X RECEPTORS 
 
 Liver X receptor (LXR) is a ligand-regulated member of the nuclear receptor superfamily 
of transcription factors. LXR functions as an intracellular sensor of excess cholesterol and as 
such, upregulates genes involved in intestinal cholesterol absorption, the conversion of 
cholesterol to bile acids, reverse cholesterol transport, lipogenesis, and inflammation. These 
genes include: CYP7a1, ABCA1, ABCG5, ABCG8, SREBP-1c, FAS, LPL, CETP, PLTP, 
ApoE, ApoCI, ApoCII, and ApoCIV (48). 
 LXR-α is expressed in liver, intestine, adipose tissue, kidney, and macrophages, whereas 
LXR-β is expressed ubiquitously. Structurally, LXR contains a DNA-binding domain and a 
ligand-binding domain. To function, LXRs form obligate heterodimers with retinoic X receptors 
(RXRs) in order to bind to liver X receptor response elements (LXRE) in the promoter regions of 
target genes.  The DNA binding domain of LXR is comprised of two zinc-fingers, while its 
ligand-binding domain lies within the C-terminal terminal region; this domain binds to 
oxysterols and cholesterol derivatives such as 24(S)-hydroxycholesterol and 24(S), 25-
epoxycholesterol. Binding of these endogenous ligands increases the transcriptional activity of 
LXR (49, 50).  
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 Evidence that LXR also plays a major role in regulating lipogenesis comes from LXR-
deficient mice, which show a clear deficiency in hepatic expression of SREBP-1c, SCD-1, and 
FAS (51). Promoter analysis of ACC1, CYP7A1, SREBP-1c, FAS, ABCA1, GLUT4, PEPCK, 
and G6Pase indicate that these are direct targets of LXR (50, 52).  
 A role for polyunsaturated fatty acids in mediating these actions of LXR has been 
determined. Polyunsaturated fatty acids bind directly to LXR-α and they repress the activation of 
LXR-α by oxysterols (53). Polyunsaturated fatty acids also interfere with the DNA-binding of 
LXR-α to target gene LXREs (54). Therefore, part of the inhibitory effect of polyunsaturated 
fatty acids on lipogenesis is to antagonize this nuclear receptor. 
 
ii. PEROXISOMAL PROLIFERATOR-ACTIVATED RECEPTORS 
 
 Another action of dietary polyunsaturated fatty acid is to increase the capacity for hepatic 
β-oxidation through the activation of peroxisome proliferator-activated receptors (PPARs); 
transcription factors that induce genes for β-oxidation, lipid transport, and thermogenesis (55, 
56). The most important gene targets of PPARs include carnitine palmitoyltransferase, 
peroxisomal acyl-CoA oxidase, uncoupling protein-3, fatty acid transport proteins, long-chain 
acyl-CoA synthetase, and pyruvate dehydrogenase kinase (57, 58).  
There are three isoforms of PPARs ( α, δ, γ) encoded by separate genes and activated by 
specific compounds; PPAR-α is expressed in liver, heart, kidney, and intestine. PPAR-δ is 
widely expressed, including in brain, adipose, and skin. The PPAR-γ gene is alternatively spliced 
to produce three PPAR-γ isoforms (γ1, γ2, γ3) that are expressed in adipose, colon, retina, and 
mammary gland (44).  
PPARs are members of the nuclear hormone receptor superfamily; as such, they are 
transcription factors that act upon DNA response elements as heterodimers with retinoic X 
receptors (RXRs) (59, 60). Like other nuclear hormone receptors, they contain a ligand-binding 
domain and two zinc finger motifs for binding to its cognate DNA sequences, which are 
comprised of a direct repeat with a single nucleotide space (DR1 elements)(60).  
Endogenous PPAR ligands include non-esterified unsaturated fatty acids, and binding of 
intracellular non-esterified polyunsaturated fatty acids and their metabolites activate this 
transcription factor; therefore, PPARs act as intracellular non-esterified fatty acid sensors (61). 
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Additionally, PPAR-α is activated by fibrates, PPAR-γ is activated by eicosanoids, and PPAR-δ 
is activated by prostanoids (44).  PPARs were first described in rodents as transcription factors 
that bind fibrates and subsequently upregulate peroxisomal proliferation and fatty acid oxidation 
(59, 62). While PPARs in humans are also responsive to fibrates, they do not induce peroxisomal 
proliferation. Instead, they induce peroxisomal fatty acid oxidation, a process that metabolizes 
very long chain fatty acids for mitochondrial β-oxidation. This action of PPARs has been 
manipulated in humans by the administration of fibrate drugs to lower cholesterol and serum 
lipid concentrations. In humans, the main role of PPARs is to induce the expression of oxidative 
genes during starvation and gluconeogenesis.  
The direct role of polyunsaturated fatty acids in mediating the activity of PPAR-α is still 
unclear, in that different sources of polyunsaturated fatty acids may have drastically different 
effects on its activity. Specifically, it has recently been observed that fatty acids derived from 
hepatic triacylglycerol hydrolysis, but not as greatly from β-oxidation, serve to activate PPAR-α 
(63). This is a novel finding pointing towards a possible intracellular partitioning mechanism for 
fatty acids derived from exogenous sources versus lipogenesis, triacylglycerol hydrolysis or β-
oxidation. 
 
iii. STEROL REGULATORY ELEMENT BINDING PROTEIN-1C 
 
Sterol regulatory element binding proteins (SREBPs) are major regulators of lipogenesis 
and cholesterol metabolism (64, 65). There are three SREBP isoforms, SREBP-1a, -1c, and -2. 
SREBP-1a and -1c are encoded by the same gene, but differ in their inclusion of the first exon 
after an alternative transcription start site (66). SREBP-2 is encoded by a different gene (66, 67). 
Both SREBP-1a and -1c regulate lipogenic genes, but the expression of SREBP-1c predominates 
in the liver of experimental animals in the fed state, whereas SREBP-1a and SREBP-2 are 
expressed in all tissues and in actively dividing cell lines (68). Although there is an overlap in the 
functions of SREBP-1 and -2, SREBP-2 is primarily involved in the transcriptional activation of 
genes involved in cholesterol uptake and synthesis (69, 70). The regulation of SREBP-1c will be 
the focus of the rest of this section. 
The transactivation domain of SREBP-1c is composed of a stretch of acidic residues, a 
proline-rich domain, and a basic/helix-loop-helix/leucine zipper (bHLH-LZ) that facilitates 
  13 
 
SREBP-1c dimerization, transport into the nucleus, and DNA-binding activity. This bHLH-LZ 
domain contains a specific tyrosine residue for binding to sterol response elements (SRE) in the 
promoter of its target genes. Lipogenic genes regulated by SREBP-1c include ACC, FAS, 
GPAT, SCD, and delta5-and delta-6-desaturases (71-74). Cholesterol metabolism genes 
regulated by SREBP-1c include the LDL receptor, HMG-CoA reductase, and HMG-CoA 
synthase, and SREBP itself (69). 
 SREBP-1c is synthesized as a precursor protein, which is inserted in the ER membrane. 
A membrane-spanning domain anchors it to the ER membrane. All three isoforms contain an N-
terminal 480 amino acids which function as the bHLH-LZ transcription factor, a region of 80 
amino acids which contain the transmembrane spanning domains across the ER membrane, and a 
regulatory C-terminal domain containing 590 amino acids (75). In order for SREBPs to become 
active, the membrane-bound SREBP must be transported from the ER to the Golgi, where the N-
terminal fragment is cleaved and can enter the nucleus. SREBPs are escorted from the ER to the 
Golgi by Scap (76). Scap itself is regulated by the binding of another protein, Insig-1; when Scap 
binds to Insig-1, Scap is unable to transport SREBP to the Golgi, and SREBP target gene 
expression declines (76-78).  
Both insulin and carbohydrate-rich diets are strong regulators of SREBP-1c. Re-feeding 
mice a high carbohydrate diet increases the expression of SREBP-1c in liver, whereas starvation 
decreases SREBP-1c mRNA expression (75, 79, 80). Importantly, this dietary paradigm does not 
effect the expression of the other SREBP isoforms. The effect of insulin on SREBP-1c gene 
expression is blocked by the actions of glucagon and an increase in cAMP (81, 82).  The 
transcriptional regulation of SREBP-1c is due to the presence of both an SRE and an LXRE 
within the SREBP-1 promoter region (83).  LXR agonists promote LXR heterodimer formation 
with RXR, which potently activate SREBP-1c expression (52, 84).The transcriptional activation 
of SREBP-1c by insulin requires the LXRE (85). The basal expression of SREBP-1c is due to 
the SRE within its promoter that binds to mature SREBP-1c in a feed-forward mechanism (85). 
 Regulation of SREBP-1c by insulin occurs at a posttranscriptional level by increasing 
the processing of inactive membrane-bound SREBP-1c to the active nuclear form (86). This 
stimulation occurs within the first two hours of insulin treatment in primary rat hepatocytes (87). 
In mouse liver and primary rat hepatocytes, insulin inhibits the expression of Insig-2a, another 
isoform of Insig-1, but insulin does not inhibit the expression of Insig-1 (which is mainly 
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affected by changes in intracellular sterol levels)(88, 89). Therefore, one mechanism by which 
insulin can stimulate hepatic lipogenesis is through in promotion of SREBP-1c transport to the 
Golgi for maturation. The responsiveness of SREBP-1c to insulin allows active SREBP-1c to 
bind and activate the transcription of lipogenic genes, which are also responsive to insulin 
stimulation and carbohydrate feeding.  
 Insulin requires the activities of PI3K and AKT to mediate its effects on SREBP-1c. 
Over-expression of constitutively active AKT in primary hepatocytes stimulates the post-
translational processing of SREBP-1 (90). This regulation requires ERK activity. Loss of PI3K 
activity corresponds to a loss in the insulin induction of SREBP-1c (91, 92). Additional 
regulation of SREBP-1c may be mediated by the insulin activation of atypical protein kinase C 
(93, 94). 
 Diets rich in polyunsaturated fatty acids inhibit SREBP-1, but not SREBP-2, through 
several mechanisms, including an inhibition of its rate of transcription, and through a decrease in 
the processing of the mature protein (46). In liver, polyunsaturated fatty acids inhibit SREBP-1a 
and -1c mRNA expression through an LXR-dependent mechanism (95). Polyunsaturated fatty 
acids inhibit SREBP-1c processing by inhibiting the degradation of Insig-1, which leads to an 
increase in its availability and the retention of SREBP-1c at the ER membrane (96). Therefore, 
when polyunsaturated fatty acids are high, or when cholesterol is abundant, mature SREBP-1c 
cannot induce the expression of lipogenic or cholesterol synthesis genes (76, 78).  
It remains to be determined whether SREBP-1c plays any role in the regulation of genes 
that are not regulated at a transcriptional level but whose mRNA accumulation is inhibited by 
polyunsaturated fatty acids, such as G6PD and ME. It is possible that SREs may still be found in 
the promoters of genes encoding splicing factors and other genes involved in posttranscriptional 
regulation.  
 Interestingly overexpression of SREBP-1c in primary hepatocytes is not sufficient to 
induce the mRNA expression of lipogenic genes to the extent that is seen with treatment with 
high glucose and insulin in wild-type hepatocytes (97). Additionally, SREBP-1c-deficient mice 
are unable to fully induce fatty acid synthesis in response to a high carbohydrate feeding (98). 
These findings suggested that another transcription factor must function to induce lipogenic and 
glycolytic mRNA expression when animals are red a high-carbohydrate diet, or when 
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hepatocytes are treated with glucose. This transcription factor (ChREBP) will be discussed in the 
next section. 
 
iv. CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN 
 
 Carbohydrate response element binding protein (ChREBP) was first identified by affinity 
chromatography as the transcription factor responsible for mediating the increase in expression 
of both lipogenic and glycolytic genes in response to a high carbohydrate diet (99). ChREBP is 
found in almost all tissues, but is most abundant in tissues with increased lipogenic capacity, 
such as liver and adipose tissues (99, 100). ChREBP is composed of a bHLH-LZ domain, and 
LZ-like domain, and a nuclear localization signal, and a polyproline domain. ChREBP binds to 
carbohydrate response elements (ChOREs) within the promoter regions of target genes. These 
ChORE elements are composed of two E boxes (with the canonical CACGTG DNA sequence) 
that form cognate sequences for bHLH-LZ transcription factors (101, 102).  
 Through ChIP assays and through overexpression studies, the direct binding of ChREBP 
to the promoters of lipogenic and glycolytic genes was observed and characterized. When 
ChREBP is deficient, the induction of FAS, ACC, and LPK in response to high glucose is no 
longer observed (103, 104). ChREBP must bind its obligate heterodimer partner Mlx, Max-like 
protein X, in order to function as a transcription factor. Two of these ChREBP heterodimers are 
then able to bind the E boxes within promoter (105-107).  
 The regulation of ChREBP is still undefined. ChREBP mRNA expression is induced by 
glucose and high carbohydrate re-feeding in hepatocytes or intact animals (103). The cellular 
localization of ChREBP changes in response to glucose, and this appears to occur coincident 
with a change in phosphorylation status. This mechanism appears to be the primary regulator of 
ChREBP, and it involves at least one dephosphorylation of ChREBP near its nuclear localization 
signal by protein phosphatase 2A (PP2A) that is responsive to the glucose status of the cell. This 
dephosphorylation event allows ChREBP to translocate to the nucleus to bind to target gene 
promoter elements. In contrast, during low-glucose conditions, this same site is phosphorylated 
in response to PKA and is unable to transcriptionally activate its target genes in the nucleus (108-
110).  
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 AMP-activated protein kinase (AMPK) is also responsible for phosphorylating ChREBP 
when intracellular AMP levels are high. AMPK activation keeps ChREBP out of the nucleus in 
order to maintain intracellular energy catabolism (111). The regulation of ChREBP 
phosphorylation and dephosphorylation, and the potential role for this as a signal for nuclear 
translocation is still very unclear, however, because a phosphorylation-defective mutant 
ChREBP is still responsive to glucose. Additionally, it has been shown that the phosphorylation 
status does not correlate with a change is glucose status in primary hepatocytes (although the 
expression of ChREBP target genes does reflect glucose status in these cells)(112).   
 The mechanism by which carbohydrate regulates both the expression and activity of 
ChREBP is unknown. In addition, the corresponding regulation of its obligate heterodimer Mlx 
is also unknown. However, a role for ChREBP regulation by polyunsaturated fatty acids is clear. 
Just as polyunsaturated fatty acids are potent inhibitors of hepatic lipogenesis (in large part due 
to their inhibition of SREBP-1c), polyunsaturated fatty acids are also effective at inducing 
ChREBP mRNA degradation and inhibiting its nuclear translocation. This effect may stem from 
the inhibitory role of polyunsaturated fatty acids on the glycolytic pathway (103, 108). Just as 
polyunsaturated fatty acids inhibit SREBP-1c through a transcriptional mechanism involving 
LXR, a similar mechanism may function in the regulation of ChREBP by polyunsaturated fatty 
acids (53, 113).  
  
b. POSTTRANSCRIPTIONAL REGULATION OF LIPOGENIC GENES BY 
 POLYUNSATURATED FATTY ACIDS  
 
Posttranscriptional regulation can occur at several points during the life span of an 
mRNA. These include pre-mRNA processing in the nucleus (capping, splicing, and 
polyadenylation), export from the nucleus, stability of the mature RNA in the cytoplasm, and 
regulation of the proteins that control these events. Dietary nutrients including carbohydrate, 
cholesterol, iron, and polyunsaturated fatty acids have been shown to regulate the expression of 
several genes through control of these molecular events. In response to a polyunsaturated fatty 
acid-enriched diet, both the rate of transcription and processing of the nuclear precursor mRNA 
of tricarboxylate carrier protein was inhibited (114). Treatment of hepatocytes with insulin 
significantly enhances the efficiency of processing of Spot-14 nuclear precursor mRNA to 
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mature mRNA (115, 116). SREBP-1c is also regulated at a posttranscriptional mechanism, in 
response to polyunsaturated fatty acids; this mechanism involves the inhibition of processing of 
the membrane-bound precursor SREBP-1c to its active nuclear form (117).  
The most well defined gene that is regulated at a posttranscriptional step in response to 
changes in diet is G6PD.  For G6PD, treatment of hepatocytes with polyunsaturated fatty acid 
results in a decrease in the splicing efficiency of the pre-mRNA in the nucleus.  This regulation 
of G6PD by dietary polyunsaturated fatty acids will be the focus of the rest of this section. 
 
i. G6PD: REGULATION BY A POSTTRANSCRIPTIONAL MECHANISM 
 
G6PD is the rate-limiting enzyme in the pentose phosphate pathway. G6PD catalyzes the 
first reaction in this pathway by converting glucose-6-phosphate to 6-phosphogluconolactone 
(118-120). NADPH is concomitantly produced during this reaction, and serves as a source of 
reducing equivalents for fatty acid biosynthesis and for cellular detoxification (121). This 
pathway provides 50-75% of the NADPH used in lipid biosynthesis, as well as the sugar-
phosphate moieties that are necessary for nucleotide biosynthesis and nucleotide coenzyme 
formation (Figure 4)(119).  
 
FIGURE 4. 
 
 
 
G6PD is found in all cells (122). Mutations in the gene result in an increased 
susceptibility to oxidative stress due to the loss of NADPH and its ability to reduce free radicals 
and peroxides. In humans, the disease associated with a partial loss of G6PD activity is known as 
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Favism (123, 124). The disease is caused by point mutations in the G6PD gene, and diminishes 
(but does not abolish) the activity of the enzyme. G6PD-deficiency results in reduced serum 
lipoprotein levels, demonstrating the importance of G6PD in generating NADPH for fatty acid 
synthesis (123). Chronic non-spherocytic hemolytic anemia can also occur in individuals with 
more severe mutations, again emphasizing the important role of NADPH in defending against 
oxidative stress (125). There is no known complete deletion of G6PD in humans; knock-out 
mutations are embryonic lethal in mice, and it is hypothesized that a complete loss of G6PD 
would be fatal in humans as well (126).  
 While G6PD is expressed constitutively in all tissues, it is regulated both nutritionally 
and hormonally in liver, adipose tissue, and lactating mammary glands, all of which are tissues 
that undergo high rates of lipogenesis (120). It has been shown that insulin increases the 
expression of G6PD, whereas polyunsaturated fat inhibits its expression (28, 127). This 
regulation by polyunsaturated fat is expected, as polyunsaturated fat has been shown to inhibit 
other lipogenic enzymes in the same manner.  
Over a normal diurnal cycle, G6PD mRNA accumulation in mouse liver changes up to 7-
fold with the consumption of food (128, 129). When mice are starved, G6PD mRNA 
accumulation is decreased; it takes 30 h for G6PD mRNA levels to maximally increase by 17-
fold upon re-feeding (130, 131). Inclusion of polyunsaturated fat in the re-fed diet, however, 
causes a decrease in G6PD activity and mRNA accumulation. Within 4h of re-feeding 
accumulation of G6PD mRNA is decreased by 80%, and a maximal inhibition occurs after 9h 
(129, 130). Arachidonic acid treatment of primary rat hepatocytes also causes a decrease in 
G6PD mRNA accumulation over a similar time course (with a maximal inhibition of G6PD 
mRNA at 8h) (130).  
The rate of transcription of the G6PD gene does not change after dietary manipulations, 
including starvation, re-feeding, and the inclusion of polyunsaturated fat in the diet both in the 
intact mouse liver and in primary hepatocytes (127, 130). The accumulation of G6PD mRNA 
does change by up to 30–fold after these manipulations. By isolating total RNA from both the 
nucleus and the cytoplasm of mouse livers after both starvation/re-feeding and the inclusion of 
polyunsaturated fat in the diet, it was determined that a change in accumulation of G6PD nuclear 
precursor mRNA precedes a change in the accumulation of mature G6PD mRNA in the 
cytoplasm (130). Therefore, G6PD is exclusively regulated by polyunsaturated fatty acid at a 
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nuclear posttranscriptional step (127). 
 Within the nucleus, a pre-mRNA must be capped, spliced, and polyadenylated in order to 
be competent for translation in the cytoplasm. All of these events present an opportunity for 
regulation. For G6PD, the addition of the 7-methylguanine cap and polyA tail is not regulated in 
response to polyunsaturated fatty acid (127). G6PD is regulated by a change in the efficiency of 
splicing. There is an accumulation of partially and fully spliced G6PD mRNA in the nucleus of 
re-fed mouse liver, whereas there is less accumulation of these mRNA species in the starved 
animal livers (132). This same nuclear posttranscriptional mechanism occurs when mice are re-
fed a diet enriched in polyunsaturated fat. Animals re-fed this diet have a decreased 
accumulation of the partially and fully spliced G6PD mRNA, in comparison to animals re-fed a 
diet low in polyunsaturated fat (129). The decreased accumulation of fully spliced G6PD mRNA 
corresponds to a decrease in G6PD protein expression, because less efficiently spliced mRNA 
species (those that are unspliced or only partially spliced) are degraded through one of two 
pathways, either by the nuclear exosome or nonsense mediated decay (133, 134). As the pre-
mRNA is degraded, there is less corresponding G6PD mRNA in the cytoplasm to be translated. 
 The mechanism for splicing requires RNA sequence elements within both the intron and 
exon, though these elements do not have strong consensus sequences. Exons also contain 
sequence elements that regulate splicing, including exon splicing enhancers (ESE) and exon 
splicing silencers (ESS). In order for splicing to occur, the exons must be correctly defined, the 
introns must be excised, and the surrounding exons joined. This process requires five small 
nuclear RNAs (U1, U2, U4, U5, U6 snRNAs).  
 RNA splicing also requires trans-acting factors, such as the serine-arginine rich (SR) 
proteins and the heterogeneous nuclear ribonucleoproteins (hnRNPs). SR proteins bind ESEs in 
order to enhance splicing, while hnRNPS bind to ESSs to inhibit splicing (135-139). However, 
there are some examples of SR proteins inhibiting splicing and hnRNPs stimulating splicing 
(140, 141). These cofactors can be regulated by changes in their subcellular localization (they 
reside inactively in nuclear speckles), and by changes in their phosphorylation state (142-144). 
Therefore, existing questions in this field include, 1) understanding the specific trans-acting 
factors that bind to and regulate each gene, 2) how specific trans-acting factors bind to cis-acting 
RNA elements, and finally 3) how this binding regulates splicing. 
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 The sequence elements within G6PD that are essential to its regulation by 
polyunsaturated fat have been determined. A cis-acting element resides within exon 12 of G6PD 
and is responsible for directing less-efficient splicing of the G6PD pre-mRNA (47). The binding 
of hnRNP A2/B1, hnRNP K, and hnRNP L to this element correlates with splicing inhibition 
(145). Additionally, the specific SR protein involved in stimulating G6PD splicing has been 
identified as SRp20 (Walsh, C.M., manuscript in preparation). The interaction of this SR protein 
within the G6PD regulatory region is thought to stimulate G6PD splicing (Walsh, et al 
unpublished). The identification of the specific trans-acting factors, and the subsequent 
regulation of those factors in response to diet is quite novel. It is also necessary in elucidating the 
intracellular mechanisms that mediate changes in gene expression in response to diet. 
 While it has been determined that G6PD is inhibited by polyunsaturated fat through 
changes in splicing efficiency of the pre-mRNA, the molecular signaling pathway by which this 
occurs has also been characterized. In primary rat hepatocytes, insulin stimulates G6PD 
expression through activation of the PI3K, resulting in the accumulation of G6PD mRNA (146). 
Polyunsaturated fatty acids, specifically arachidonic acid, inhibit this accumulation of G6PD 
mRNA in response to insulin. Polyunsaturated fat mediates this effect through the activation of 
p38 MAPK and the subsequent serine phosphorylation of IRS-1. Additionally, arachidonic acid 
treatment results in a decrease in AKT activation (146).  
 A role for AMP-activated protein kinase (AMPK) has also been described for the 
regulation of G6PD by polyunsaturated fatty acid (147). AMPK activity is increased when 
hepatocytes are treated with arachidonic acid, and this activation coincides with a decrease in 
G6PD mRNA. Activation of AMPK by pharmacological activators mimics the effect of 
arachidonic acid on G6PD mRNA. Finally, when hepatocytes express a nonfunctioning AMPK, 
arachidonic acid is unable to inhibit G6PD mRNA (147). Whether AMPK works solely through 
its activation of p38 MAPK, or through the activation of another signaling molecule to regulate 
G6PD is unclear.  
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VI. INSULIN SIGNALING AND ITS REGULATION BY POLYUNSATURATED 
 FATTY ACID 
 
 Insulin is arguably the most important hormone in the body for maintenance of whole 
body energy homeostasis. No other hormone is as potent a regulator of metabolic events 
throughout so many different target tissues. Insulin is secreted from β-cells in the pancreatic 
islets of Langerhans in response to increases in circulating blood glucose. The main function of 
insulin is to maintain plasma glucose concentrations of 4-7 mM; these concentrations are 
maintained during the re-fed condition due to the coordinated actions of insulin on tissues such 
as muscle, adipose, liver, and pancreas. Insulin stimulates glucose uptake in muscle and adipose 
after the ingestion of carbohydrate, and conversely inhibits glucose production and secretion 
from liver during this same period. Therefore, insulin tightly controls the source of glucose for 
energy use during both starvation and re-feeding by controlling whether or not the liver or a 
carbohydrate-rich meal is the major source of glucose in the blood. 
 Insulin stimulates GLUT4 translocation to the cell surface in adipose and muscle for 
glucose uptake into those tissues. Up to 75% of insulin-dependent glucose uptake occurs in 
skeletal muscle, where that glucose is primarily used to provide energy (ATP) to working 
muscles. In adipose tissue insulin stimulates glucose uptake and its conversion to triacylglycerol 
for energy storage.  
 Beyond maintaining blood glucose levels of 4-7 mM, insulin also functions in the liver to 
maintain whole body energy homeostasis. While insulin does not stimulate glucose uptake by the 
liver, it coordinately inhibits hepatic glycogenolysis and gluconeogenesis, and stimulates hepatic 
glycolysis and lipogenesis (148). Therefore, insulin acts to coordinate energy consuming versus 
energy storage pathways, which are essential for providing energy (in the form of fatty acids and 
glucose) to the rest of the body during postprandial period. The effects on lipogenesis occur 
primarily through the insulin regulation of lipogenic gene expression, as described above.  
 Disruption in insulin signaling has serious effects on energy homeostasis, leading to 
pathological concentrations of glucose and fatty acids circulating in the blood. From a clinical 
perspective, this is evidenced by the poor health of people with diabetes and obesity-related 
insulin resistance, in which insulin signaling is extremely disturbed (149). Insulin resistance is 
defined by defects in the ability of insulin-sensitive tissues to respond appropriately to the 
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presence of insulin; these defects include an increase in serine phosphorylation of the insulin 
receptor substrates (especially IRS-1 and IRS-2), and a prolonged activation by insulin of the 
down-stream signaling kinases. In skeletal muscle and liver, increased intracellular 
triacylglycerol and high circulating non-esterified fatty acids is associated with insulin resistance, 
and makes these tissues insensitive to increases in circulating insulin (149). This appears to be 
due to disregulation of intermediate proteins and kinases, which will be discussed in the 
preceding sections.  
 
a. INSULIN RECEPTOR 
 
 Insulin exerts its metabolic effects on target tissues through its interaction with the insulin 
receptor. The insulin receptor is made up of two extracellular α-subunits that transduce the 
insulin signal to cytosolic β-subunit kinase domains. The  β-subunits then trans-auto-
phosphorylate each other at specific tyrosine residues. These phosphorylated tyrosine residues 
function in two distinct capacities: either as part of the catalytic portion of the β-subunits or as 
docking sites for proteins that interact with the phosphorylated insulin receptor (150).  
 
b. INSULIN RECEPTOR SUBSTRATES 
 
Of at least ten intracellular substrates that can bind the insulin receptor, the insulin 
receptor substrates (IRS) are the major adaptor proteins that bind to the phosphorylated tyrosine 
residues of the activated insulin receptor (151). There are four isoforms of IRS (IRS-1, -2, -3, -
4), all of which contain a pleckstrin homology (PH) domain and a phospho-tyrosine-binding 
domain (PTB) (151). IRS proteins also contain several tyrosine phosphorylation motifs 
(YXXM), which become tyrosine phosphorylated by the activated insulin receptor (152). It is 
through these domains that IRS proteins recruit other adaptor proteins with Src homology 2 
(SH2) domains. The two major SH2-containing proteins that bind to IRS proteins are Grb2 and 
PI3K (1, 149, 150). Grb2 transmits the insulin signal to the Ras-MAP kinase pathway, 
stimulating growth and differentiation (153), while PI3K promotes the metabolic actions of 
insulin within the cell (154).  
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The isoforms of IRS vary in their tissue distribution as well as their precise role in 
mediating the insulin signal. IRS-1 and IRS-2 are widely expressed in mammalian tissues; IRS-3 
is expressed predominantly in adipose tissue, while IRS-4 is mainly expressed in embryonic 
kidney. IRS-1 and IRS-2 appear to play overlapping functions in activating PI3K; in fibroblasts, 
the knockout of IRS-1 (and the subsequent loss of insulin signaling) can be reversed with 
overexpression of either IRS-1 or IRS-2. Whole body IRS-1 knockout demonstrates a role for 
IRS-1 in mediating growth, because these animals are growth retarded, whereas IRS-2, -3, and -4 
knockout mice are of normal size (155-159). Additionally, IRS-1 knockout mice only become 
mildly insulin resistant, likely because IRS-2 (or the other IRS isoforms) can substitute for the 
IRS-1 in these cells (160). However, IRS-2 knockout mice become overtly diabetic (157). Loss 
of IRS-3 and -4 does not lead to a disruption in insulin sensitivity (161).  
While the exact function of each IRS protein has not been clearly defined in all tissues, 
much is known about the regulation and importance of IRS-1 to insulin signaling in liver. The 
phosphorylation of IRS-1 is integral to maintenance of insulin responsiveness (162), and the 
serine phosphorylation of IRS-1 leads to a desensitization of the insulin response (1, 163). 
Phosphorylation of IRS-1 at ser307, ser612, and ser632 uncouples IRS-1 from the insulin receptor 
and occludes PI3K binding sites (1, 164, 165). This negative regulatory phosphorylation is 
mediated by a variety of kinases, including MAP kinases, PKC, mTOR, S6K, and IKK, and in 
response to various stimuli, including excess free fatty acids (1, 166-169).  In both muscle and 
liver, the accumulation of intracellular triacylglycerol results in a decrease in IRS-associated 
PI3K activity (170).  
 
c. PHOSPHOINOSITIDE 3-KINASE 
 
 PI3K plays a major role in propagating the insulin signal for the regulation of metabolic 
events (171). In fact, both pharmacological inhibitors and dominant negative forms of the kinase 
completely block the effects of insulin on lipogenic gene expression. PI3K is a heterodimeric 
protein that contains a catalytic and regulatory domain (p110 and p85 subunits, respectively). 
The p85 regulatory domain interacts with tyrosine-phosphorylated IRS-1 and IRS-2 through their 
SH2 domains (1, 171, 172). There are 3 catalytic domain isoforms and at least eight different 
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regulatory domain isoforms that differ in their tissue distribution. The combination of these 
subunits provides different tissue specificity and insulin responsiveness to PI3K. 
 PI3K is responsible for the phosphorylation of membrane phosphoinositides, which 
recruit signaling molecules to the membrane including serine/threonine kinases, Rho GTP-ases, 
and the TEC-family of tyrosine kinases (173). When PI3K is associated with IRS-1, the p85 
regulatory subunit can no longer bind to the p110 catalytic subunit. The relief of this allosteric 
inhibition allows the p110 domain of PI3K to phosphorylate membrane phosphoinositides to 
form the second messenger phosphatidylinositol (3,4,5)-triphosphate (PIP3), which can then bind 
to proteins containing PH-domains. The presence of PIP3 then recruits 3-phosphoinositide-
dependent protein kinase1 (PDK1), a serine/threonine kinase, to the membrane. PDK1 then 
phosphorylates and activates AKT and also the atypical protein kinase C family members (1, 
174).  
 
d. AKT 
 
 AKT is a PH-domain containing serine/threonine kinase, which lies directly downstream 
of PI3K. AKT mediates the actions of insulin on intracellular metabolism, and is absolutely 
required to transduce the insulin signal. The three isoforms of AKT (α, β, and γ) vary in their 
tissue distribution; AKT-α is the active isoform expressed in muscle and liver, AKT-β is the 
predominant isoform activated in adipose, while AKT-γ is only insulin-responsive in cell culture 
models (175). All the isoforms of AKT require activation by PI3K (176). 
 AKT becomes activated after the formation of PIP3 at the membrane by active PI3K. The 
formation of PIP3 recruits both AKT and its upstream kinase phosphoinositide-dependent 
protein kinase-1 (PDK1) to the membrane. There, AKT is phosphorylated at thr308 by PDK1 
(174, 177). AKT also becomes phosphorylated at ser473 by the mammalian target of rapamycin 
(mTOR)-rictor complex (178). Both phosphorylations are required for the full activity of AKT.  
Through these phosphorylations, AKT is able to mediate insulin actions on glycogen synthesis, 
glucose transport, lipogenesis, and gluconeogenesis. 
 Activated AKT phosphorylates target proteins at serine residues. These target proteins 
include glycogen synthase kinase 3 (GSK 3), 6-phosphofructo-2-kinase, the Forkhead family of 
transcription factors (including FOXO-1), mTOR, Raf, and pro-apoptotic BAD (179). Through 
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these phosphorylations, AKT is able to mediate insulin actions on glycogen synthesis, glucose 
transport, lipogenesis, and gluconeogenesis. AKT phosphorylates GSK3 at ser21 and ser9, thereby 
inactivating it.  This action of AKT results in increased glycogen synthase activity and therefore 
glycogen synthesis when glucose is abundant (180). AKT phosphorylation of FOXO-1, which 
occurs during insulin treatment or re-feeding, activates FOXO-1 and the expression of its target 
lipogenic and gluconeogenic genes (181-184).  AKT mediates the effects of insulin on protein 
translation through its activation of mTOR and thereby its downstream target S6K. Cell survival 
is promoted through the AKT inactivation of BAD and apoptosis. Finally, AKT promotes 
crosstalk between PI3K and MAPK through its phosphorylation of Raf (185). Insulin activates 
the Ras–Raf–MAPK pathway through the activation of the small GTPase Ras. Ras activated Raf, 
which phosphorylates and activates MEK1 and MEK2. MEK1/2 are the upstream activators of 
ERK1/2 (186). AKT is also important to many of the downstream effects of insulin on cell 
survival and lipogenesis. Overexpression of active AKT can recapitulate the effects of insulin on 
G6PD and several other lipogenic genes (187-190)(Kohan, A.B., unpublished data).    
 
e. ATYPICAL PROTEIN KINASE C (ζ/λ) 
 
Atypical protein kinase C is a downstream target of PI3K and the insulin receptor. There 
are two isoforms of atypical protein kinase C, PKC ζ and PKCλ (191).  They are homologous in 
their catalytic domain, but play different roles during development. Based on knockout studies, 
PKC λ is necessary for embryonic development, and is embryonic lethal (192). However, PKC ζ 
knockout has not been demonstrated to have phenotyptic differences (192). PKC ζ/λ are 
serine/threonine kinases, containing a conserved catalytic domain and a regulatory domain. 
Unlike the novel and conventional PKCs, PKC ζ/λ is not sensitive to changes in intracellular 
calcium (193, 194).   
Insulin stimulates the phosphorylation and activation of PKC ζ/λ through the formation 
of PIP3 and the recruitment of PDK-1 to the cell membrane. PDK-1 phosphorylates PKC ζ/λ at 
serine/threonine residues within its activation loop. Complete activation of PKC ζ/λ also requires 
PIP3-dependent auto-phosphorylation (195-197). PKC ζ/λ is activated by insulin, but this 
activation differs from other major PI3K targets (such as AKT) in that it requires IRS-2, but not 
IRS-1; this demonstrates a separate role for PKC ζ/λ activation along with PI3K in mediating 
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intracellular metabolism (198). 
Although PKC ζ/λ has been shown to be an important regulator of cell growth, survival, 
and inflammation through its interaction with nuclear-factor –  κB, PKC ζ/λ has recently been 
shown to play an important role in the insulin induction of SREBP-1c in liver (199-201).  In 
hepatocytes, the loss of PI3K results in a loss of SREBP-1c induction by insulin. However, this 
effect can be rescued by reconstitution with PKC ζ/λ, rather than AKT, indicating that PKC ζ/λ is 
the major downstream target of PI3K responsible for SREBP-1c regulation (186, 202). This 
suggests that PKC ζ/λ activation may regulate many lipogenic genes, whereas AKT may be more 
important for the regulation of glucose metabolism. However, the full library of PKC substrates 
has not been determined.  
Elevated free fatty acids have also been shown to activate PKC isoforms, including PKC 
ζ/λ (203, 204). This activation contributes to insulin resistance, since PKC ζ/λ can then 
phosphorylate and inactivate the IRS proteins (205-207). The extent to which free fatty acids or 
dietary polyunsaturated fatty acids activate PKC ζ/λ in the liver is still unknown.  
 
f. AMP-ACTIVATED PROTEIN KINASE 
  
 AMP-activated protein kinase (AMPK) is involved in the cellular response to metabolic 
stresses and the maintenance of energy homeostasis. AMPK is a master metabolic sensor, and it 
acts as an upstream mediator of signaling pathways that respond to diet, hormones, and other 
cellular stresses. AMPK is a sensor of cellular energy because it is activated by an increase in the 
AMP/ATP ratio (208). Overall, this leads cells to abandon energy-consuming pathways (such as 
glycogen and fatty acid synthesis) and to stimulate energy-producing pathways (such as fatty 
acid oxidation and glycolysis).  These actions of AMPK are required to replenish and stabilize 
cellular ATP levels. 
 AMPK is expressed ubiquitously among all mammalian cells, and it is highly conserved 
in all eukaryotes. AMPK is a heterotrimeric protein composed of a catalytic α-subunit and two 
regulatory β- and γ-subunits.  AMPK is allosterically activated by AMP, which binds 
cooperatively to its γ-subunits. Upon binding of AMP, AMPK becomes a better target for its 
upstream kinase LKB1, which promotes full activation of AMPK through the phosphorylation of 
thr172 within the kinase domain of the α-subunit. LKB1 forms a heterotrimer with the proteins 
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MO25 and STRAD, which is required for the catalytic activity of the kinase. LKB1 appears to be 
constitutively active, because activators of AMPK do not activate the kinase activity of LKB1 
(209, 210). AMP binding also inhibits dephosphorylation at thr172 by protein phosphatase 2C 
(208).  
 AMPK plays a regulatory role in numerous cellular processes both catabolic and anabolic 
in nature. Perhaps the most well understood result of AMPK activation is the phosphorylation 
and inactivation of acetyl-coA carboxylase (ACC) at ser79, ser1200 and ser1215 (211, 212).  ACC 
catalyzes the conversion of acetyl CoA to malonyl CoA and is the rate-limiting enzyme of the 
fatty acid synthesis pathway. Malonyl CoA is not only required for fatty acid synthesis, but it 
also acts as an allosteric inhibitor of CPT-1, the rate-limiting enzyme in fatty acid oxidation in 
mitochondria. AMPK powerfully regulates this axis by inhibiting fatty acid synthesis and 
stimulating fatty acid oxidation. 
 Metabolic conditions such as glucose deprivation, ischemia, hypoxia, and hyper-osmotic 
stress activate AMPK, as cellular conditions that increase the intracellular AMP/ATP ratio (213, 
214). Another metabolic effect of AMPK is that AMPK mediates the beneficial effects of two 
widely prescribed anti-diabetic drugs, Metformin and rosiglitazone; specifically, the activation of 
AMPK in liver by these drugs ameliorates some diabetic symptoms including excess weight gain 
(215). It is thought that the mechanism involves increases in cellular β-oxidation, and therefore a 
decrease in stored triacylglycerol. It is likely that the role of AMPK in mediating hepatic energy 
metabolism will continue to expand; however, it seems likely that AMPK will continue to 
emerge as a regulator of large scale changes in metabolic homeostasis rather than a player in the 
fine-tune control of metabolism in response to varied stimuli (such as specific dietary 
components).  
 
g. MITOGEN-ACTIVATED PROTEIN KINASES 
 
 The phosphorylation of proteins at serine and threonine residues is a major mechanism in 
the regulation of metabolism, growth, differentiation, apoptosis, and gene expression. A major 
class of serine/threonine kinases mediating signal transduction in response to extracellular 
stimuli is the mitogen-activated protein kinases (MAPK)(216, 217). Mitogen-activated protein 
kinases (MAPKs) are activated by specific extracellular stimuli and act alone and in concert to 
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effect rapid intracellular responses to those stimuli. Mammalian MAPKs include p38 MAPK, c-
Jun n-terminal kinase (JNK), and extracellular signal-related kinases (ERK 1/2).  
 The cascade that regulates all the MAPKs consists of a MAPK kinase kinase (MKKK) 
and a MAPK kinase (MEK), leading to the sequential activation of the MAPK itself. MEKs 
recognize and phosphorylate the thr-X-tyr motif in the activation loop of all MAPKs, which are 
themselves serine/threonine kinases. MEKs are regulated by serine/threonine kinases and their 
cellular localization. The most common MAPK substrates are transcription factors, whose 
activities are regulated by phosphorylation (such as transcription factors downstream of estrogen, 
insulin, and glucocorticoid receptors)(216-219).  
 
h. EXTRACELLULAR SIGNAL-REGULATED KINASE 
 
 Different MAPK cascades have been identified, but the best characterized in mammalian 
cells is the extracellular signal-regulated kinase (ERK) pathway. This leads to the activation of 
ERK1 and ERK2.  A role for ERK 1/2 in cell growth and survival is well understood in a variety 
of tissues; however, a role for this MAPK in mediating the insulin signaling pathway and 
lipogenesis is just emerging. ERK 1/2 are 44 and 42 kDa proteins expressed in all tissues. ERK 
1/2 are phosphorylated by MEK1 and MEK2, and are activated in response to treatment with 
fatty acids, growth factors, and cell stress (220). Erk1 and Erk2 are generally activated together, 
share greater than 85% sequence identity, and appear to serve a redundant role in the cell (217, 
218, 221). 
 ERK 1/2 is rapidly phosphorylated when cells are treated with insulin, and there is some 
evidence that ERK functions to antagonize the intracellular insulin response in response to 
polyunsaturated fatty acid (90). In this respect, ERK activation by n-3 polyunsaturated fatty acid 
(specifically docosahexaenoic acid) activates ERK, while also inhibiting the insulin stimulation 
of AKT. This activation of ERK mediates the proteasomal degradation of SREBP-1c in response 
to polyunsaturated fatty acids (90, 219, 222). This data suggests a role for ERK in mediating 
hepatic lipogenesis, yet it remains to be seen whether this role is specific for the lipogenic 
pathway or whether ERK functions to antagonize insulin signaling after a variety of stimuli. 
 
i. p38 MAPK 
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 p38 mitogen-activated protein kinase (p38 MAPK) is a 38 kDa member of the mitogen-
activated protein kinase superfamily. p38 MAPK contains a TGY activation loop, which is 
phosphorylated by upstream kinases MKK3/6 for full activation (223).Rac and CDC42 are also 
upstream activators of p38 MAPK (224). A potential role of AMPK upstream of p38 MAPK has 
also been suggested, but has not yet been shown definitively (147, 225, 226). Downstream 
targets of p38 MAPK include cAMP response binding protein (CREB), activating transcription 
factor –1 and-2 (ATF1, ATF2), CHOP, p53, C/EBP, and IRS-1 and -2 (223, 227). Through its 
effect on these transcription factors, p38 MAPK action can direct gene expression during times 
of cellular stress. 
 Activation of p38 MAPK occurs in response to a variety of cellular stimuli (228-230). In 
various tissues, these include the inflammatory cytokines, growth factors, G protein-coupled 
receptor activation, and other cell stressors (231). Elevation of plasma non-esterified fatty acids 
is a known activator of p38 MAPK (232). This activation results in an intracellular protective 
response mediated by p38 MAPK, leading to events such as the production of heat shock 
proteins, immune responses, cell differentiation, or cell death.  
 In addition to its role in mediating cellular stress responses in a variety of tissues, p38 
MAPK also plays a role in energy homeostasis in tissues such as brown adipose, muscle, and 
hepatocytes. p38 MAPK activation stimulates the mitochondrial oxidation, thermogenesis, and 
gluconeogenesis (233-238). p38 MAPK is activated by cAMP and glucagon in isolated 
hepatocytes, and through this activation p38 MAPK inhibits hepatic lipogenesis through its 
inhibition of SREBP-1c expression (238). In whole animals, p38 MAPK is activated in liver by 
fasting, and knock-down of p38 MAPK results in an elevation in circulating plasma 
triacylglycerol as well as hepatic triacylglycerol content (238). In response to non-esterified fatty 
acids, p38 MAPK is phosphorylated and the transcription of gluconeogenic genes are stimulated 
(such as PEPCK and G6Pase)(238). p38 MAPK also inhibits the posttranscriptional regulation of 
G6PD in liver in response to polyunsaturated fatty acids (146).  
 This data strongly suggests a central role for p38 MAPK in liver, in mediating the cellular 
response to fasting and re-feeding, as well as to specific nutrients in the diet (such as 
polyunsaturated fatty acids and glucose).  However, the exact mechanism by which p38 regulates 
lipogenesis in the liver has not been established. 
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j. c-JUN N-TERMINAL PROTEIN KINASE 
 
 The c-Jun N-terminal protein kinases (JNK1/2/3) bind to and phosphorylate c-Jun, a 
component of the AP-1 transcription complex. JNK proteins are 46 and 54 kDa, and JNK1/2/3 
share greater than 85% sequence identity  (239).  JNK is a stress-activated protein kinase that is 
highly responsive to cytokines, g-protein coupled receptor activation, growth factors, and many 
other extracellular stimuli (217, 240). Like all other MAPKs, JNK is activated by upstream 
MEKKs and MEKs through phosphorylation within their thr-X-tyr loop. JNK activation results 
in cytokine production, the inflammatory response, apoptosis, actin reorganization, and cell 
transformation (241).  
JNK phosphorylation is induced during diabetes and insulin resistance, possibly due to an 
increase in intracellular oxidative stress and the subsequent activation of MEK 4/7 (242); this 
activation of JNK leads to impairments in the insulin-signaling pathway because JNK can inhibit 
IRS-1 (through ser307 phosphorylation), and may also mediate some of the apoptotic effects of 
high circulating free fatty acids (2, 243-245).  Knockdown of JNK in mice has been shown to 
improve type 2 diabetes, as well as a reduction in body weight and atherosclerosis (2, 245). 
While JNK definitely plays a role in antagonizing the insulin signal during times of stress, it does 
not appear that JNK plays a specific role in mediating the cellular response to normal 
physiological changes, such as the availability of nutrients between meals, or the response to 
different nutritional stimuli. 
 
VII. PHYSIOLOGY OF LIPID DIGESTION, ABSORPTION, AND UPTAKE BY THE 
LIVER 
 
a. ANIMAL AND CELL CULTURE MODELS 
 
 For over 30 years it has been known that individuals with high circulating blood lipid 
levels can ameliorate this condition by including polyunsaturated fatty acids in their diets. The 
intracellular mechanism for this regulation is still unknown. Beginning in 1958, the work of Hill 
et al established that the rate of fatty acid synthesis in liver, and the activity of key lipogenic 
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enzymes, was regulated by an increase in polyunsaturated fatty acids included in a mouse or rat 
diet (30). It was determined that polyunsaturated fatty acids of the n-3 and n-6 varieties inhibit 
hepatic lipogenesis at low levels in the diet, and that this inhibition is not due to a decrease in 
carbohydrate intake (246, 247). This finding prompted additional study of specific unsaturated 
fatty acids on the inhibition of hepatic lipogenesis (31-33, 246, 248-250).  
 In order to examine specific factors that influence hepatic gene expression, primary rat 
hepatocytes in culture have been the predominant model. The effects of non-esterified fatty acids 
on primary hepatocytes have been studied in order to address the mechanisms by which dietary 
fatty acids exert their inhibitory effects on hepatic lipogenesis; although this experimental 
paradigm has been incredibly useful in describing these mechanisms, we must be careful in 
broadly applying these results to the intact animal because this model mimics the physiological 
state only during starvation and uncontrolled diabetes. During these conditions, one of the 
mediators of the inhibitory effects of polyunsaturated fatty acid on lipogenesis is non-esterified 
fatty acid. Non-esterified fatty acids are released from adipose tissue into the blood during 
starvation (or during uncontrolled diabetes), when lipolysis is stimulated by glucagon and results 
in the hydrolysis of free fatty acid from glycerol (251). These non-esterified fatty acids are 
released from adipose tissue and travel through the blood bound to serum albumin. The non-
esterified fatty acids are taken up by liver, where they bind to intracellular fatty acid binding 
proteins, and they become substrates for: β-oxidation, elongation and desaturation, 
triacylglycerol, phospholipid, and cholesterol synthesis, and may be converted to prostanoids 
(17). Although the effects of non-esterified fatty acids in primary hepatocytes generally mimic 
the effect of starvation in intact animal, it is important to consider that the mechanisms by which 
dietary fatty acids exert their inhibitory effects are still unknown. The physiology of dietary fat 
digestion, transport, and uptake by the liver (and how this differs from the transport of lipolysis-
derived non-esterified fatty acids) is described below. 
 
b. DIETARY LIPID DIGESTION, ABSORPTION, AND HEPATIC METABOLISM  
 
 Dietary triacylglycerol and other lipid components are energy dense and water-insoluble. 
Without significant processing, dietary lipid would not be available to peripheral tissues in a 
usable state. The general mechanism by which lipid is digested begins with its emulsification, 
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rendering it able to diffuse into the lumen of the enterocyte. Emulsification is accomplished both 
mechanically, by the mouth and stomach, and chemically, by the addition of cholesterol, 
phospholipids, protein, and polysaccharides to the emulsion particle in the stomach. As dietary 
triacylglycerol is hydrophobic, it resides in the interior of the emulsion particles. 
 Both lingual and gastric lipases work to hydrolyze the triacylglycerols associated with 
each emulsion particle. The action of these enzymes releases a single fatty acid and 
diacylglycerol (which both remain in the emulsion particle for further digestion in the intestine). 
In the small intestine the lipid components of emulsion particles are next acted upon by 
pancreatic lipase, colipase, carboxyl ester hydrolase, and phospholipase A2, which are secreted 
from the pancreas. The net result of these enzymes is the hydrolysis of lipid into its free fatty 
acid, 2-monoacylglycerol, free cholesterol, and lysophospholipid components.  
 As triacylglycerol is further hydrolyzed into free fatty acid and other lipid breakdown 
products, the emulsion particle becomes much smaller and is now called a mixed-micelle.  The 
breakdown products converge at the surface of the enterocyte, where they either diffuse or are 
transported through the enterocyte membrane into its lumen. 
Once in the enterocyte, these breakdown products are re-esterified into triacylglycerols, 
phospholipids, and cholesterol esters. Within the enterocyte, these products are then incorporated 
into a lipoprotein particle called a chylomicron. The chylomicron contains triacylglycerol and 
cholesterol in its core, surrounded by phospholipids and apolipoprotein B-48 on its exterior 
(252). Chylomicrons are then secreted into the intestinal lymphatic capillaries, and into the blood 
stream via the thoracic lymph duct (where they acquire ApoC-II and ApoE from the HDL pool) 
(253).  
 Chylomicrons interact with lipoprotein lipase on the surface of capillary endothelial cells. 
Lipoprotein lipase hydrolyzes triacylglycerol in the chylomicrons, releasing free fatty acids that 
can diffuse into peripheral tissues for β-oxidation or storage (254). Free fatty acids, released from 
the chylomicron, may enter cells via fatty acid transport proteins (FATP), through simple 
diffusion, or through yet unidentified transporters (255). Fatty acids are then used as substrates 
for β-oxidation, elongation, desaturation, and for biosynthesis of active compounds (45).  
As chylomicrons are acted upon by lipases at the peripheral tissues, their fatty acid and 
cholesterol content decreases, producing a smaller, denser particle known as a chylomicron 
remnant that is ultimately taken up by the liver (252). The LDL receptor and the LDL-receptor 
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related protein (LRP) are the primary proteins involved in chylomicron remnant removal (57). 
Roles for hepatic lipase, phospholipase, and heparin sulfate proteoglycans (HSPG) have also 
been described (57). It remains to be seen which of these pathways predominates. However, it is 
known that ApoE is necessary for the uptake of chylomicron remnants, as ApoE-depleted 
remnants will not be cleared (256).  
Lysosomal enzymes in the liver hydrolyze the triacylglycerol that is left in the remnant as 
it is taken into the hepatocyte. This is a major source of fatty acid for the liver (257). 
Chylomicron remnants are enriched in fatty acids from the diet, therefore, the triacylglycerols 
that are taken up by the liver from chylomicron remnants also represent the same types of fats 
present in the diet (Figure 5)(258, 259). 
 
FIGURE 5. 
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c. FREE FATTY ACID TRAFFICKING ACROSS THE CELL MEMBRANE 
 
 There are several evolutionarily conserved proteins responsible for the transport and 
metabolism of fatty acids entering the mammalian cell. These include at least 6 fatty acid 
transport proteins (FATP) and 5 long-chain acyl CoA synthetases (Acsl), which facilitate the 
unidirectional transport of fatty acids across the cell membrane through vectorial acylation (260). 
The roles of each of these isoforms are not clear, although they vary in tissue distribution and 
substrate specificity. Vectorial acylation is the process by which fatty acids enter the cell 
concomitantly with their esterification to CoA thioesters, making the fatty acyl CoA unable to 
diffuse back across the membrane. In this reaction, catalyzed by Acsl, substrate fatty acid, CoA, 
and ATP are required to form the acyl-CoA product and AMP.  
 Acsl possess activity towards long chain fatty acids, and each isoform is expressed in a 
unique pattern among tissues and within cellular organelles. The fact that there are many 
isoforms, located in a distinct intracellular pattern, with different substrate specificities, suggests 
that each isoform may have a distinct function. Acsl 1,4, and 5 are the predominant isoforms in 
liver (261). Interaction with specific FATP and/or Acsl classes seems to render the fatty acyl 
CoA more available to specific metabolic pathways within the cell. For example, it has now been 
shown that Acsl 4 activation of fatty acids directs these products towards mitochondrial  β-
oxidation, whereas interaction with other isoforms may direct fatty acyl CoA products towards 
cytoplasmic de novo lipogenesis (261).  
 Vectorial acylation is not the only mechanism for bringing exogenous free fatty acids into 
the cell. Fatty acids, like other hydrophilic compounds, are able to bind the cell membrane. 
Through this mechanism, they are thought to enter the cell through binding and flipping between 
the two leaflets of the cell membrane (262-264). Fatty acid transport combines delivery to the 
membrane, flipping between the leaflets, and protein-mediated mechanisms to then “pull” the 
fatty acids away from the membrane. Recently, it has been suggested that the flip between the 
membrane leaflet requires energy and possibly a specific FATP isoform, although this 
mechanism is poorly understood (265-267). The kinetics of this process are still unknown; 
especially, whether this process is saturable without protein chaperones, or whether it may occur 
in the presence of another fatty acid transport protein such as CD36 (267). However, CD36 
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expression does not correlate with changes in the rate of fatty acid uptake (261). FATP isoforms, 
however, have been shown to directly interact with Acsl at the cell membrane (261).  
 Tissues with high rates of fatty acid uptake and lipid metabolism also have high levels of 
expression of one or more fatty acid binding proteins (FABPs). FABPs are cytoplasmic proteins 
that bind to both saturated and unsaturated fatty acids, and are involved in their transport 
between membranes (268, 269). Liver-type FABP (LFABP) is involved in lipid absorption and 
VLDL metabolism in liver, and is one of the most abundant proteins in liver (270). The 
functional importance of LFABP is demonstrated by LFABP-null mice, which have severe 
defects in β-oxidation, due to a lack of substrate availability (271, 272). Additionally, LFABP-
null mice are protected from hepatic steatosis when they are fed a high-fat diet, unlike their wild-
type counterparts (271, 272). LFABP has been found in the nucleus, where it directly interacts 
with PPAR-α to mediate gene expression (273). Due to differences in the affinity of LFABP 
binding to saturated versus unsaturated fatty acids, LFABP may be involved in partitioning fatty 
acids to specific metabolic pathways. 
 The availability of so many isoforms of intracellular proteins that bind fatty acids 
suggests that there are many factors influencing the binding of fatty acid to each isoform and the 
subsequent partitioning of that fatty acid to a specific metabolic pathway. That these factors may 
include the source of fatty acid (either from non-esterified fatty acid entering the cell during 
starvation, or from the hydrolysis of dietary triacylglycerol) is an important and unknown 
consideration in understanding how dietary polyunsaturated fat regulates energy homeostasis. 
  
VIII. HYPOTHESIS 
 
As described above, the potential for dietary polyunsaturated fatty acids to impact 
metabolic processes is significant. However, the specific mechanisms by which dietary 
polyunsaturated fatty acids inhibit de novo lipogenesis have been determined through 
experiments in which albumin-bound polyunsaturated fatty acids are added to primary rat 
hepatocytes in culture (40). This experimental model assumes that adding free fatty acids to 
cultured cells, which will increase the intracellular fatty acid concentration, will result in the 
same metabolic changes as dietary fat. This is an untested assumption.  
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This model has serious limitations, not the least of which is that dietary polyunsaturated 
fat is not delivered to the liver as non-esterified fatty acids. Dietary triacylglycerol enters the 
peripheral circulation from the intestine as a nascent chylomicron and is taken up by the liver as 
a chylomicron remnant (252), which is significantly different from the uptake of albumin-bound 
fatty acid, which occurs predominantly during starvation.   
As described above, there is evidence that the mode of entry of lipid into the hepatocyte 
can dictate its metabolic fate. Acyl-CoA synthetases are able to channel long chain fatty acids to 
specific metabolic pathways, specifically, non-esterified fatty acids entering via Acsl 1 appears 
to partition to the microsome for de novo lipogenesis, whereas fatty acids encountering other 
Acsl isoforms may partition towards β-oxidation (274-276).  
 The goal of these experiments is to define the differences between chylomicron remnant 
triacylglycerol and non-esterified polyunsaturated fatty acids in the regulation of hepatic de novo 
fatty acid synthesis, as well as their roles in the signal transduction mechanism. These 
experiments provide evidence for significant differences in the regulatory potential between 
albumin-bound non-esterified fatty acids and dietary triacylglycerol in the hepatocyte. This 
finding is novel, and is crucial in understanding the physiological effects of dietary fat on liver.  
These mechanisms are necessary for our understanding of metabolic diseases such as type 2 
diabetes, heart disease, and metabolic syndrome, which all share defects in the ability of the liver 
to properly respond to dietary fat.  
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ABSTRACT: 
Both polyunsaturated fatty acids and AMPK promote energy partitioning away from 
energy consuming processes, such as fatty acid synthesis, towards energy generating processes, 
such as β-oxidation. In this report, we demonstrate that arachidonic acid activates AMPK in 
primary rat hepatocytes, and that this effect is p38 MAPK-dependent. Activation of AMPK 
mimics the inhibition by arachidonic acid of the insulin-mediated induction of G6PD.  Similar to 
intracellular signaling by arachidonic acid, AMPK decreases insulin signal transduction, 
increasing Ser307 phosphorylation of IRS-1 and a subsequent decrease in AKT phosphorylation. 
Overexpression of dominant-negative AMPK abolishes the effect of arachidonic acid on G6PD 
expression. These data suggest a role for AMPK in the inhibition of G6PD by polyunsaturated 
fatty acids.  
 
 
 
 
 
 
KEYWORDS: polyunsaturated fatty acids, lipogenesis, primary hepatocytes, AMP-activated 
protein kinase. 
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INTRODUCTION: 
 Polyunsaturated fatty acids have multiple regulatory actions within cells including 
activating cellular signaling pathways and regulating gene expression.  The mechanism by which 
polyunsaturated fatty acids transduce their signal within cells is not completely understood.  The 
inhibition of acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), and spot 14 (S14) 
expression in rat liver by polyunsaturated fatty acids is associated with the activation of AMP-
activated protein kinase (AMPK) [1; 2; 3]. Yet, the ability of dietary polyunsaturated fatty acids 
to activate AMPK in all tissues is not uniformly observed and a role for AMPK in regulating the 
transcription of glucose-responsive genes is controversial [4; 5; 6; 7]. Therefore, we asked if a 
lipogenic gene regulated exclusively at a posttranscriptional level would involve AMPK activity 
in the inhibition of its expression by polyunsaturated fatty acids.   
 Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme in the pentose 
phosphate pathway. G6PD catalyzes the first reaction in this pathway by converting glucose-6-
phosphate to 6-phosphogluconolactone [8; 9; 10]. NADPH is concomitantly produced during this 
reaction, providing 50-75% of the necessary reducing equivalents for fatty acid biosynthesis in 
liver [9]. G6PD expression is inhibited by polyunsaturated fat through a posttranscriptional 
mechanism involving decreases in the efficiency of splicing of the pre-mRNA [11]. The 
signaling pathway causing increased expression of G6PD involves insulin activation of the 
phosphatidylinositol 3-kinase (PI 3-kinase) pathway resulting in the accumulation of G6PD 
mRNA [12]. Polyunsaturated fatty acids such as arachidonic acid inhibit accumulation of G6PD 
mRNA by inhibiting insulin signaling through the activation of p38 mitogen activated protein 
kinase (p38 MAPK) and the subsequent Ser307 phosphorylation of insulin receptor substrate-1 
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(IRS-1) [12]. Upstream kinases stimulating the phosphorylation of p38 MAPK have remained 
elusive. 
 AMPK has been suggested to play a role in mediating the actions of fatty acids in cells. 
AMPK is a sensor of cellular energy because it is activated by an increase in the AMP/ATP ratio 
[13].  Activation of AMPK leads cells to abandon energy-consuming pathways (such as 
glycogenolysis and fatty acid synthesis) and to stimulate energy-producing pathways (such as β-
oxidation and glycolysis).  Polyunsaturated fatty acids have a similar activity within cells via the 
short-term inhibition of ACC activity that regulates both fatty acid synthesis and oxidation, as 
well as via long-term changes in the expression of genes in glycolysis, lipogenesis and fatty acid 
oxidation [14].  
 Due to the coinciding roles of both polyunsaturated fatty acids and AMPK in energy 
homeostasis, the role of AMPK in mediating the inhibitory effects of polyunsaturated fatty acids 
on lipogenic enzymes seems probable. In this report, we demonstrate that AMPK is an inhibitor 
of G6PD expression and that inhibition of AMPK activity abrogates the inhibitory action of 
polyunsaturated fatty acids on the accumulation of G6PD mRNA. 
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MATERIALS AND METHODS: 
 
Animal care and cell culture - Male Sprague-Dawley rats (150-200g) were maintained on 
standard rodent chow under a normal light-dark cycle. Animal experiments were conducted in 
conformity with the Public Health Service policy on Humane Care and Use of Laboratory 
Animals, additionally; the Institutional Animal Care and Use Committee of the Division of 
Laboratory Animal Resources at West Virginia University approved all experimental procedures. 
Hepatocytes were isolated from the liver by a modification of the method of Seglen [15], as 
described previously [11]. Hepatocytes (3 x 106) were plated onto 60 mm collagen-coated plates 
in Hi/Wo/Ba medium (Waymouth MB752/1 plus 20 mM HEPES, pH7.4, 0.5 mM serine, 0.5 
mM alanine, 0.2% bovine serum albumin) plus 5% newborn calf serum to facilitate cell 
adhesion. Two hours post-isolation hepatocytes were washed twice with serum-free media, and 
were incubated overnight with serum-free media and 0.3 mg Matrigel per plate (BD 
PharMingen) at 37°C in a humidified atmosphere of 5% CO2 and 95% air. Treatments were 
added to the hepatocytes in fresh serum-free media, without Matrigel, after 20 h in culture (time 
zero). Hepatocytes not receiving 175 µM arachidonic acid (Nu-Check Prep: complexed with 4 
mM bovine serum albumin and butylated-hydroxytoluene 0.1%) were treated with an equivalent 
volume of serum free media containing 4 mM bovine serum albumin and butylated-
hydroxytoluene 0.1% solution. All media contained supplemental a-tocopherol (5µg/ml of 
medium). The AMPK activator, aminoimidazole carboxamide ribonucleotide (AICAR) was 
purchased from Toronto Research Chemicals Inc. The p38 MAP kinase inhibitor, SB203580 was 
purchased from Calbiochem.  
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Protein isolation and Western blot analysis - Preparation of cell lysates and western analysis 
was as described [12].  The primary antibodies against phosphorylated AKT (Ser473), 
phosphorylated IRS-1 (Ser307), phosphorylated p38 MAPK (Thr180/Tyr182), phosphorylated 
AMPK (Thr172), phosphorylated ACC (Ser79), phosphorylated PKC (pan, βII Ser660), 
phosphorylated S6K-1, (Thr389), phosphorylated MAP kinase kinase (MKK) 3/6 and total AKT, 
IRS-1, p38 MAPK, AMPK, ACC, tubulin were obtained from Cell Signaling Technology. Anti-
rabbit IgG conjugated with horseradish peroxidase (Cell Signaling Technology) was used as the 
secondary antibody, and the immunocomplexes were detected by enhanced chemiluminescence 
(Pierce). Images were visualized with film (Pierce) and quantified by densitometry using 
ImageQuant software (Amersham Biosciences).  
 
Adenoviral Vectors — Adenovirus expressing dominant-negative AMPK (kinase-dead due to 
K45R mutation in α2 subunit, with a 5’ myc tag)(a gift from Dr. M. Birnbaum)[16] and 
adenovirus expressing green fluorescent protein (GFP; a gift from Dr. C.J. Rhodes)[17] were 
amplified in HEK 293 cells. Virus was purified by CsCl gradient in which the virus was layered 
over 1.25 g/ml CsCl in 100mM Tris (pH 8.0) and 1.4 g/ml CsCl in 100mM Tris (pH 8.0), and 
spun at 35,000 rpm for 1 h at 4˚C in a SW-41 rotor. The viral band was excised and overlayered 
with 1.34 g/ml CsCl in 100mM Tris (pH 8.0) and spun at 60,000 rpm for 10 h at 4˚C in a VTi 
65.2 rotor. The viral fraction was then desalted using a sephadex G-25 column (Pharmacia). 
Viral titer was determined using the Adeno-X Rapid Titer kit (Clontech) per the manufacturer’s 
instructions. The purified virus was stored in 30% glycerol in PBS at -80˚C. 
 
Isolation of Total RNA and quantitative real-time RT-PCR - Total RNA was isolated from 
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two plates per treatment using Tri-Reagent (Ambion) according to manufacturer’s instructions. 
Abundance of specific mRNA was measured using real-time reverse transcriptase polymerase 
chain reaction (RT-PCR). RNA (150-200 ng) was DNase I-treated and expression of all mRNAs 
was determined by real-time PCR (BioRad iCycler iQ) analysis.  G6PD and RPL32 mRNAs 
were measured using TaqMan probes. ACC, SCD, FAS, S14, and cyclophilin B mRNAs were 
measured using Quantitect SYBR green (QIAGEN) according to the manufacturer’s instructions. 
Sequences for primers and probes are as follows glucose 6-phosphate dehydrogenase, sense, 5'-
TATGTCTATGGCAGCCGAGGT-3', antisense, 5'- GCAGAGTGCAGATGGTGTAAG -3'; 
fatty acid synthase, sense, 5'-TGCAACTGTGCGTTAGCCACC-3', antisense, 5'-
TGTTTCAGGGGAGAAGAGACC-3'; stearoyl-coA desaturase, sense, 5'-
AGCTCAGCCAAATGCTGTGTTGTC-3', antisense, 5'-
TGCCTTGATCAGTCACAGACACCT-3'; spot 14, sense, 5'-
CAGGAGGTGACGCAGAAATAC-3', antisense, 5'-GTGAGGTAAATACAGCGTCCC-3'; 
cyclophilin B, sense, 5'-CGTGGGCTCCGTTGTCTT-3', antisense, 5'-
TGACTTTAGGTCCCTTCTTCTTATC-3’; RPL32, sense, 5’-
AAACTGGCGGAAACCCAGAG-3’; antisense, 5’-GCAGCACTTCCAGCTCCTTG-3’; G6PD 
probe, 5'-FAM/CCACAGAGGCAGATGAGCTGATGAAGAA/3BHQ-3'; RPL32 probe, 5’-/56-
FAM/CCAGATCCTGATGCCCAACATTGC-3’. The relative amount of each mRNA was 
calculated using the comparative threshold cycle method. Expression of cyclophilin B or RPL32 
was used as a control and the amount of each mRNA was calculated relative to this control. 
 
  70 
 
Statistics – Statistics were performed using GraphPad Prism (version 4.0). Overall statistical 
significance was determined by one-way ANOVA; multiple comparisons were made using a 
Bonferroni post-test if the overall p-value after ANOVA was p<0.05. 
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RESULTS: 
 Phosphorylation of AMPK at Thr172 is a measure of AMPK activation [13]. Incubation of 
primary rat hepatocytes with arachidonic acid induced AMPK phosphorylation compared to cells 
not treated with insulin or arachidonic acid (NA or I); total AMPK levels did not change (Fig. 1). 
The activation of AMPK in response to arachidonic acid was rapid and was detected as early as 
10 min and retained through 60 min (data not shown). ACC phosphorylation at Ser79 was 
induced by treatment with arachidonic acid further indicating that arachidonic acid activates 
AMPK and its downstream targets in rat hepatocytes (Fig. 1)[18; 19]. Coincident with the 
activation of AMPK, p38 MAPK and its upstream kinase MKK 3/6 were also activated (Fig. 1). 
The coincident activation of these signaling molecules supports the hypothesis that the AMPK 
signaling pathway as well as the inhibitory p38 MAPK pathway are cooperating to inhibit G6PD 
expression.  
 To test for a role of AMPK signaling in the inhibition of G6PD expression, accumulation 
of G6PD mRNA was measured after treatment with AICAR, a pharmacological activator of 
AMPK [20]. Insulin induced G6PD mRNA accumulation five-fold compared to no addition, and 
the addition of AICAR to the hepatocytes inhibited this increase by 50% (Fig. 2A). This mimics 
the extent of inhibition of G6PD mRNA by arachidonic acid [12]. The abundance of G6PD 
mRNA is expressed relative to RPL32 mRNA abundance.  In all experiments, RPL32 expression 
was not regulated by AICAR (data not shown).  Hepatocytes were also treated with metformin, 
another pharmacological activator of AMPK, to test if AMPK activation by a different 
compound can also inhibit G6PD expression [21]. Like AICAR, metformin also inhibited the 
insulin-induction of G6PD mRNA by 50% or more (data not shown). As expected, AICAR 
enhanced AMPK phosphorylation in these cells (Fig. 2B).  In addition, this stimulation of 
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AMPK was accompanied by a 5-fold increase in p38 MAPK activation as compared to insulin 
alone (Figs. 2B and 2C). Thus, activation of AMPK by AICAR mimics the effect of arachidonic 
acid on G6PD expression and p38 MAPK activation. 
 Arachidonic acid activation of p38 MAPK is accompanied by phosphorylation of IRS-1 
at Ser307, which decreases insulin signal transduction and ultimately inhibits G6PD expression 
[12]. Incubation with AICAR also induced Ser307 phosphorylation of IRS-1 (Fig. 2D). In 
addition, the insulin-mediated activation of AKT, a measure of PI 3-kinase activity, was 
completely abolished in the presence of AICAR. These results suggest that like arachidonic acid, 
activation of AMPK with AICAR interferes with the PI 3-kinase pathway resulting in a decrease 
in the expression of G6PD mRNA. 
 In order to determine whether the activation of p38 MAPK by AICAR plays a role in the 
inhibition of G6PD, hepatocytes were treated with the p38 MAP kinase inhibitor SB203580. 
Insulin induced G6PD mRNA accumulation by 3-fold despite the presence of SB203580; 
however, the AICAR-mediated inhibition of the G6PD mRNA expression was completely 
abolished (Fig. 3A). Thus, the AICAR-mediated inhibition of G6PD mRNA expression involves 
the p38 MAP kinase pathway. 
 The effect of AMPK activation by AICAR on the expression of other lipogenic genes 
was also determined.  In primary rat hepatocytes, insulin stimulates the accumulation of mRNA 
for FAS, SCD, and S14 by 3 to 10-fold (Fig. 3B). The insulin stimulation of these genes was 
inhibited by AICAR, 53%, 55% and 59%, respectively. Treatment with the p38 MAP kinase 
inhibitor SB203580 blocked this effect of AICAR on these genes. The abundance of these 
mRNA is expressed relative to cyclophilin.  AICAR and SB203580 did not affect the abundance 
of cyclophilin mRNA indicating the selectivity of these treatments (data not shown).  Therefore, 
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other lipogenic genes are inhibited when AMPK is activated, and this inhibition is attenuated 
when p38 MAPK activity is blocked.  
 To confirm a role of AMPK in the arachidonic acid mediated inhibition of G6PD, 
hepatocytes were infected with adenovirus expressing dominant-negative AMPK. Hepatocytes 
not receiving dominant-negative AMPK were infected with adenovirus expressing green 
fluorescent protein (GFP). Infection with the dominant-negative AMPK dramatically decreased 
the activation of AMPK by arachidonic acid as measured by changes in ACC phosphorylation, a 
downstream target of AMPK (Fig. 4A).  Virus expressing GFP did not alter AMPK activity. 
Western analysis against the Myc tag of the dominant-negative AMPK further confirmed 
expression of the adenovirus in the cells (data not shown). In hepatocytes infected with the 
control adenovirus, insulin treatment induced G6PD expression by 4-fold and treatment with 
arachidonic acid significantly inhibited this stimulation by 54% (Fig. 4B). Dominant-negative 
AMPK blocked the inhibition by arachidonic acid. This data provides evidence for a role of 
AMPK in the arachidonic acid-mediated inhibition of G6PD.  
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DISCUSSION:   
Polyunsaturated fatty acids are potent regulators of cellular function and yet the signal 
transduction mechanisms that they use have remained elusive. In our previous studies, we have 
shown that arachidonic acid-mediated inhibition of insulin-induced G6PD expression involves 
the activation of p38 MAPK pathway, which in turn interferes with the PI 3-kinase pathway 
through the Ser307 phosphorylation of IRS-1, thus inhibiting the insulin-mediated induction of 
G6PD [12]. Fatty acids are also known to activate additional signaling pathways including 
AMPK [2].  In this report we present the following lines of evidence that arachidonic acid 
activation of AMPK is involved in the inhibition of G6PD expression. First, activation of 
AMPK, per se, inhibits the insulin induction of G6PD mRNA (Fig. 2A).  Second, activation of 
AMPK by AICAR concomitantly activates p38 MAPK, results in Ser307 phosphorylation of IRS-
1, and inhibits AKT phosphorylation similar to the action of arachidonic acid (Figs. 2B, 2C, and 
2D)[12]. Inhibition of p38 MAPK blocks the effect of AICAR on accumulation of G6PD mRNA 
(Fig. 3A). These changes in the activity of signaling pathways and G6PD expression occur 
within the same time frame as arachidonic acid activation of AMPK and arachidonic acid 
inhibition of G6PD expression. Finally, arachidonic acid inhibition of G6PD mRNA requires 
active AMPK, as the expression of a dominant negative AMPK blocks this inhibition (Fig. 4B). 
Thus, our data are consistent with the hypothesis that activation of AMPK by arachidonic acid 
enhances p38 MAP kinase activity resulting in the inhibition of insulin signal transduction and 
thereby G6PD expression. 
The role of AMPK in mediating the effects of polyunsaturated fats on liver metabolism is 
controversial.  Studies examining AMPK activation in response to dietary lipid are inconclusive 
[1; 4; 5; 7].  These may reflect the difficulty in retaining the phosphorylation state of proteins 
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during the preparation of tissue lysates.  Alternatively, AMPK activation may not be a primary 
mechanism in regulation by dietary fatty acids.  In this regard, incubation of rat hepatocytes with 
chylomicron remnants, the mode of delivery of dietary fat to liver, does not activate AMPK 
(Kohan and Salati, submitted for publication).  In contrast, liver is exposed to high 
concentrations of non-esterified fatty acids during times of enhanced lipolysis.  AMPK activation 
occurs rapidly in response to free fatty acids (Fig.1) and may play an important role in the 
partitioning of liver metabolism towards fatty acid oxidation and gluconeogenesis.  It is not clear 
why activation of AMPK by fatty acids is observed by some laboratories (Fig. 1)[6] and not by 
others [4; 5]. AMPK activation occurs rapidly and may require measurement at earlier time 
points or may be unique to specific fatty acids.  Alternatively, procedural differences in 
hepatocyte culture and harvesting techniques may be responsible.  Nonetheless, activation of 
AMPK by polyunsaturated fatty acids coincides with inhibition of G6PD expression. 
The activities of the lipogenic enzymes, including G6PD, are coordinately regulated. Yet, 
the details of this regulation differ between the different lipogenic enzymes.  G6PD is unique in 
that its regulation occurs primarily at a posttranscriptional step. The inhibition of G6PD and 
other lipogenic enzymes by AMPK suggests that this kinase is an important upstream signaling 
molecule impacting multiple steps in gene expression and altering the capacity of hepatocytes for 
fatty acid biosynthesis. 
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FIGURE LEGENDS: 
 
Figure 1.  Arachidonic acid induces activation of AMPK. Primary rat hepatocytes were plated 
on collagen coated dishes and incubated in Hi/Wo/Ba medium. After 20 h in culture, the medium 
was replaced with Hi/Wo/Ba with or without insulin (40 nM; I) and albumin-bound arachidonic 
acid (175 µM; AA). Total cell lysates were isolated 10 min after treatment. Western blot analysis 
was performed against phosphorylated AMPK (Thr172) and total AMPK, phosphorylated ACC 
(Ser79), and total ACC, phosphorylated MKK 3/6, and phosphorylated p38 MAPK 
(Thr180/Tyr182) and total p38 MAP kinase. A representative blot is shown. Repetition 
demonstrating the same results was as follows: n=3 experiments for phosphorylated and total 
AMPK and ACC, n=2 for P-MKK 3/6, n=7 for phosphorylated and total p38 MAP kinase. NA, 
no addition; P-AMPK, phosphorylated AMPK; P-ACC, phosphorylated ACC; P-MKK 3/6, 
phosphorylated MKK 3/6; P-p38, phosphorylated p38 MAP kinase.  
 
Figure 2.  Activation of AMPK inhibits the insulin-mediated induction of G6PD mRNA 
and insulin signal transduction. Primary rat hepatocytes were plated on collagen coated dishes 
and incubated in Hi/Wo/Ba medium. A. After 20 h in culture, the medium was replaced with 
Hi/Wo/Ba with or without insulin (40 nM; I) and AICAR (0.5 mM). Media was replaced every 
12 h with one of identical composition, and RNA was isolated after 24 h of treatment (2 
plates/treatment). G6PD mRNA is calculated relative to RPL32 mRNA. Values are expressed as 
the fold-increase over no addition (NA). Each bar represents the mean ± SE of n=4 independent 
primary hepatocyte isolations. B. After 24 h in culture, the medium was replaced with Hi/Wo/Ba 
with or without insulin (40 nM; I) and AICAR (0.5mM). Total cell lysates were isolated 10 min 
after treatments.  Western blot analysis was performed against phosphorylated AMPK (Thr172), 
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and phosphorylated and total p38 MAPK. A representative blot is shown.  C. Densitometry was 
performed with ImageQuant software (Molecular Dynamics), and values were calculated as 
arbitrary densitometric units of phosphorylated/total protein. Values are expressed as the fold-
increase over no addition (NA). Each bar represents the mean ± SE of n=4 independent primary 
hepatocyte isolations.  D. Hepatocytes were treated with or without AICAR (0.5 mM) 24h prior 
to the addition of insulin (40 nM; I). Total cell lysates were prepared 10 min after the addition of 
insulin. Western blot analysis was performed against total and phosphorylated IRS-1 (Ser307) and 
AKT (Ser473).  A representative blot is shown and represents the mean ± SE of n=4 independent 
primary hepatocyte isolations.  
 
Figure 3.  Inhibition of lipogenic genes by polyunsaturated fatty acids by AMPK requires 
p38 MAPK. After 20 h in culture, the medium was replaced with Hi/Wo/Ba with or without the 
p38 MAP kinase inhibitor SB203580 (10 µM; SB) or AICAR (0.5 mM) for 2 h. Cells were then 
treated with or without insulin (40 nM; I). Media was replaced every 12 h with one of identical 
composition, and RNA was isolated after 24 h of treatment (2 plates/treatment). A. G6PD 
mRNA is calculated relative to RPL32 mRNA. Values are expressed as the fold-increase over no 
addition (NA). Each bar represents the mean ± SE of n=4 independent primary hepatocyte 
isolations. B. FAS, SCD, and S14 mRNA abundance is calculated relative to rat cyclophilin B. 
Values are expressed as the fold-increase over no addition (NA). Each bar represents the mean ± 
SE of n=3 independent primary hepatocyte isolations.  
 
Figure 4.  Inhibition of AMPK activity blocks the arachidonic acid inhibition of G6PD 
expression. Primary rat hepatocytes were plated on collagen coated dishes and incubated in 
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Hi/Wo/Ba medium. After 2 h in culture, hepatocytes were infected with 1, 5, and 10 infectious 
units/cell of either dominant-negative AMPK expressing adenovirus (DNAMPK) or control 
adenovirus expressing GFP. After 2 h, cells were washed twice, and media was replaced with 
one containing Matrigel. After 20 h in culture, the medium was replaced with Hi/Wo/Ba with or 
without insulin (40 nM; I) and arachidonic acid (175 µM; AA). A. After 10 minutes of treatment, 
cell lysates were prepared and Western analysis was performed against phosphorylated ACC 
(Ser79) and against tubulin as a loading control.  B. For isolation of mRNA, media was replaced 
every 12 h with one of identical composition, and RNA was isolated after 24 h of treatment (2 
plates/treatment). G6PD mRNA abundance is calculated relative to rat cyclophilin B. Values are 
expressed as the fold-increase over no addition (NA). Each bar represents the mean ± SE of n=3 
independent primary hepatocyte isolations.  
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ABSTRACT: 
 
 Primary hepatocytes treated with non-esterified polyunsaturated fatty acids have been 
used as a model for describing the inhibitory effects of dietary polyunsaturated fats on lipogenic 
gene expression. This model resembles starvation or uncontrolled diabetes but not dietary fat 
ingestion, which is delivered to liver via chylomicron remnants. Chylomicron remnants enriched 
with polyunsaturated fatty acids stimulate a unique pattern of intracellular signaling. These 
remnants enhance p38 mitogen activated protein kinase (MAPK) activity but do not inhibit 
insulin signaling or induce extracellular-signal related kinase (ERK) or AMP-activated protein 
kinase (AMPK) activation as do non-esterified polyunsaturated fatty acids. Polyunsaturated fatty 
acids-enriched remnants and non-esterified polyunsaturated fatty acids both inhibit the rate of 
fatty acid synthesis and the expression of the lipogenic genes, particularly those regulated by 
sterol response element binding protein-1c (SREBP-1c). Saturated fatty acid-enriched remnants 
fail to inhibit the lipogenic genes indicating that the inhibitory action of dietary polyunsaturated 
fats involves regulatory mechanisms in liver.  In contrast, polyunsaturated fatty acids-enriched 
remnants fail to inhibit malic enzyme, glucokinase, L-pyruvate kinase, and cytochrome P450-7α 
(Cyp-7α) expression despite their inhibition by non-esterified fatty acids. These genes are 
regulated independently of SREBP-1c.  Therefore, non-esterified polyunsaturated fatty acids do 
not accurately model all aspects of regulation of hepatic metabolism by dietary fat. 
 
 
KEYWORDS: polyunsaturated fatty acids, non-esterified fatty acids, lipogenesis, dietary fat, 
nutritional regulation of gene expression, primary hepatocytes, chylomicron remnants, dietary 
triacylglycerol. 
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INTRODUCTION: 
 
Cardiovascular disease is a leading cause of morbidity and mortality in both developed 
and developing nations (1, 2). It is well established that the amount and type of fat in the diet 
plays a crucial role in the development of cardiovascular disease (1-4). Increased plasma 
triacylglycerol directly correlates with the severity and progression of atherosclerosis, and is 
associated with an increased risk of obesity, diabetes, and coronary heart disease (5, 6). Dietary 
polyunsaturated fatty acids protect against these diseases, in part by the inhibition of 
triacylglycerol synthesis and secretion from the liver (7, 8). This effect is mediated by a decrease 
in the expression of the lipogenic enzymes involved in the synthesis of fatty acids and thereby 
triacylglycerol (9-12). The actions of dietary fat are unique to polyunsaturated fatty acids of the 
n6 and n3 families.  Saturated and monounsaturated fatty acids fail to inhibit de novo lipogenesis 
(13, 14). Polyunsaturated fatty acids also enhance the clearance of triacylglycerol from the 
periphery through their inhibition of apolipoprotein (apo) CIII expression (15, 16). Additionally, 
n6 polyunsaturated fatty acids, found in vegetable oils, ameliorate cardiovascular disease through 
favorable changes in insulin signaling (7, 8, 17). The potential, therefore, of dietary 
polyunsaturated fatty acids to ameliorate atherosclerosis and metabolic diseases is significant.  
To determine the role of dietary polyunsaturated fatty acids in the inhibition of de novo 
lipogenesis, and to model their regulatory and signaling potential, albumin-bound 
polyunsaturated fatty acids are added to primary rat hepatocytes in culture (18). This model 
presumes that the increase in intracellular polyunsaturated fatty acid concentration caused by free 
fatty acids result in the same metabolic changes as dietary fat. Formal proof is lacking.  The 
model has also had a significant limitation in defining the mechanisms responsible for the 
regulatory differences between polyunsaturated fatty acids and saturated fatty acids, because 
  90 
 
incubation of primary rat hepatocytes with the saturated fatty acid, palmitate causes a rapid 
depletion in cellular ATP concentrations and stimulates apoptosis (18, 19).  Furthermore, non-
esterified polyunsaturated fatty acids do not recapitulate the manner in which fatty acids from the 
diet are delivered to liver.  
Dietary triacylglycerol is delivered to the periphery via the intestinally derived 
chylomicron. Dietary triacylglycerol and other lipid components are energy dense and water-
insoluble. Without significant processing, dietary lipid would not be available to peripheral 
tissues in a usable state. The nascent chylomicron produced in the enterocyte contains 
triacylglycerol and cholesterol in its core, surrounded by phospholipids and apo B-48 on its 
exterior (20). Nascent chylomicrons are secreted into the intestinal lymphatic vessels and enter 
the bloodstream via the thoracic lymph duct, where they acquire apo C-II and apo E from the 
HDL pool (21). Chylomicrons interact with lipoprotein lipase on the surface of capillary 
endothelial cells. Lipoprotein lipase hydrolyzes free fatty acids from triacylglycerol in the 
chylomicrons, releasing free fatty acids that enter into extrahepaptic tissues for β-oxidation or 
storage (22). Lipase interaction with the chylomicron produces a smaller, more dense particle 
known as a chylomicron remnant, which contains 15 to 35% of its original dietary triacylglycerol 
and is cleared from circulation by the liver (20). Assimilation of the remnant-derived 
triacylglycerol into the hepatocytes involves both the action of hepatic lipase on the extracellular 
surface and receptor-mediated endocytosis followed by lysosomal enzyme hydrolysis of 
chylomicron remnant triacylglycerol releasing free fatty acids (23-25). Studies examining the 
regulatory impact of triacylglycerol from the diet as chylomicron remnants are limited.  
 In contrast to fatty acids derived from lipoproteins, uptake of albumin-bound fatty acid by 
the liver represents the primary mechanism for providing cellular energy during starvation and 
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uncontrolled diabetes.  Free fatty acids are released from triacylglycerol stores in adipose tissue 
during stimulated lipolysis and enter the bloodstream where they associate with albumin 
providing a mechanism for transport the water-insoluble lipid.  Within the liver sinusoids, the 
free fatty acids dissociate from the albumin and enter hepatocytes by diffusion and/or the action 
of specific fatty acid transporters (26, 27).  Not only do the mechanisms of uptake differ between 
non-esterified fatty acids and chylomicron remnants but also the hormonal milieu is substantially 
different between the starved and the postprandial state.   
 A body of evidence is developing that support the notion that the mode of entry of lipid 
into the hepatocyte can dictate its metabolic fate. Acyl-CoAs appear to be channeled into specific 
pathways dependent upon their interaction with specific acyl-CoA synthetase (ACS) or fatty acid 
transport protein (FATP) isoforms. For example, non-esterified fatty acids entering via ACS1 
appear to partition to the microsome for triacylglycerol synthesis, whereas fatty acids 
encountering other ACS isoforms may partition towards β-oxidation (28-30). Fatty acids 
entering via FATP5 are shunted toward triacylglycerol synthesis (31).  The differential fates of 
fatty acids entering via hepatic lipase hydrolysis of remnant triacylglycerol or via lysosomal 
digestion of the remnant are not known. These data suggest that the potential for fatty acids to 
regulate lipogenic enzyme expression may also be related to their mode of entry into the 
hepatocyte. 
 The goal of these experiments is to define the differences between chylomicron remnant 
triacylglycerol and non-esterified polyunsaturated fatty acids in regulating key signal 
transduction intermediates and in inhibiting the expression of lipogenic genes.  In addition, the 
incubation of primary rat hepatocytes with chylomicron remnants derived from dietary sources 
of fat provides a novel method to test the regulatory action of polyunsaturated fatty acids versus 
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saturated fatty acids on the expression of lipogenic and glycolytic genes. The finding that there 
are significant metabolic differences between the effect of non-esterified polyunsaturated fatty 
acids and dietary triacylglycerol on the liver, in terms of both lipogenic, glycolytic, and signaling 
pathways is novel, and is crucial for understanding the physiological effect of dietary fat on liver.  
These mechanisms may be exploited for understanding the metabolic defects in diseases such as 
type-2 diabetes, heart disease, and metabolic syndrome, which all share defects in the ability of 
the liver to properly respond to dietary fat.  
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MATERIALS AND METHODS: 
  
 
Animal care and cell culture - Male Sprague-Dawley rats (150-200g) were maintained on 
standard rodent chow (unless otherwise indicated) under a normal light-dark cycle. Animal 
experiments were conducted in conformity with the Public Health Service policy on Humane 
Care and Use of Laboratory Animals, additionally; the Institutional Animal Care and Use 
Committee of the Division of Laboratory Animal Resources at West Virginia University 
approved all experimental procedures. Hepatocytes were isolated from the liver by a 
modification of the method of Seglen (32), as described previously (33). Hepatocytes (3 x 106) 
were plated onto 60 mm collagen-coated plates in Hi/Wo/Ba medium (Waymouth MB752/1 plus 
20 mM HEPES, pH7.4, 0.5 mM serine, 0.5 mM alanine, 0.2% bovine serum albumin) plus 5% 
newborn calf serum to facilitate cell adhesion. Two hours post-isolation hepatocytes were 
washed twice with serum-free media, and were incubated overnight with serum-free media and 
0.3 mg Matrigel per plate (BD PharMingen) at 37°C in a humidified atmosphere of 5% CO2 and 
95% air. Treatments were added to the hepatocytes in fresh serum-free media, without Matrigel, 
after 20 h in culture (time zero). Hepatocytes not receiving 175 µM arachidonic acid (Nu-Check 
Prep: complexed with 4 mM bovine serum albumin and butylated-hydroxytoluene 0.1%) were 
treated with an equivalent volume of serum free media containing 4 mM bovine serum albumin 
and butylated-hydroxytoluene 0.1% solution. All media contained supplemental α-tocopherol 
(5µg/ml of medium). Any additional hormones and/or treatments added are described in each 
figure legend. 
Protein isolation and Western blot analysis - After rinsing once in cold PBS, hepatocytes were 
harvested in 300 µl cell lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1mM EGTA, 1% 
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Triton X-100, 1 mM sodium orthovanadate, 1mM sodium fluoride, 2.5 mM sodium 
pyrophosphate, 1mM beta-glycerophosphate, 1X complete protease inhibitor cocktail (Roche) 
and 1mM phenylmethylsulfonyl fluoride). Hepatocytes were sonicated for 15 1-second pulses on 
ice. After centrifugation at 14,000 x g for 5 min at 4°C, insoluble debris was removed. For 
analysis of SREBP-1c cell lysates were prepared from hepatocytes as described by Hansmannel 
et al (34). The BCA protein assay kit (Pierce) was used to determine protein concentration. The 
cell lysates (20-40 µg protein) were then separated by 7.5–12% SDS-PAGE and transferred to 
polyvinylidene difluoride membranes in a transfer buffer consisting of 20 mM Tris-HCl, pH 6.8, 
154 mM glycine, and 20% methanol. Membranes were blocked with 5% nonfat dry milk in Tris-
buffered saline with 0.1% Tween and incubated with primary antibodies, followed by incubation 
with anti-rabbit IgG horseradish peroxidase-linked secondary antibody (Cell Signaling). Primary 
antibodies against phosphorylated (P) -AKT (Ser 473), P-p38 MAPK (Thr180/Tyr182), P-ERK (Thr 
202/Tyr 204), P-AMPK (Thr172), and their total forms were obtained from Cell Signaling. Total 
SREBP-1c antibody was obtained from Santa Cruz. Chemiluminescence was detected by ECL 
plus (Amersham) and imaged using film or the Typhoon 9410 (GE Healthcare). Densitometry 
was performed with ImageQuant software (Molecular Dynamics).  
Immunoprecipitation analysis - Cellular lysates (1mg total protein; pre-cleared with Protein A-
agarose beads) were incubated with 4 mg of total insulin receptor substrate (IRS)-1 antibody 
(Millipore, 06-248) for 1 h at 4°C.  Each reaction was then incubated with Protein A-agarose 
beads for an additional 1 h at 4°C.  After centrifugation, supernatants were removed and the 
beads were washed three times in cell lysis buffer, complete with protease and phosphatase 
inhibitors.  Electrophoresis sample loading buffer (80 µl) was then added to the beads and the 
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samples were boiled for 5 min and subjected to Western analysis using antibodies against 
phosphotyrosine (Millipore, 4G10 Platinum) and P-IRS-1 (Ser 307). 
Isolation of Total RNA and quantitative real-time RT-PCR - Total RNA was isolated from 6 
x 106 hepatocytes (two 60 mm plates) per treatment using Tri-Reagent (Ambion) according to 
manufacturer’s instructions. RNA (150 ng) was DNase I-treated and expression of all mRNAs 
except G6PD was determined in duplicate by quantitative real-time PCR (BioRad iCycler iQ) 
analysis using Quantitect SYBR green (QIAGEN) according to the manufacturer’s instructions. 
G6PD mRNA was determined by quantitative real-time PCR analysis using Quantitect Probe 
(QIAGEN) with the following sequence: 5'-
FAM/CCACAGAGGCAGATGAGCTGATGAAGAA/3BHQ-3'.  Sequences for primers are 
provided in supplemental Table S1. Expression of cyclophilin B was used as a control and the 
amount of each mRNA was calculated relative to this control. The relative amount of mRNA 
was calculated using the comparative threshold cycle method.  
Preparation of chylomicron remnants - Lymph fistula rats with duodenal and intestinal lymph 
duct fistulae (35) were infused (3 ml/h) with a lipid emulsion containing safflower oil or lard 
(0.36 g/animal; lard was warmed to melt it) and 19 mM sodium taurocholate in PBS (pH 6.4). 
Lymph was collected hourly for 6 h. Whole chylomicrons and remnants were isolated as 
described previously (36). Briefly, lymph was layered under 0.9% NaCl and centrifuged at 
25,000g for 60 min at 4°C in a 50 Ti fixed angle rotor (Beckman). Large chylomicrons were 
harvested by removing the top 1 to 1.5 ml fraction. Chyle triacylglycerol was digested with 
lipoprotein lipase by mixing 3 ml of the chylomicron fraction with 9 mls 5% fatty acid-free 
bovine serum albumin and 3ml of post-heparin plasma, and incubating for 1 h at 28°C. Post-
  96 
 
heparin plasma was isolated as described {Nilsson, 1977 #672}. Chylomicron remnants were 
purified by adjusting the density to 1.063 g/ml with NaCl and KBr. This solution was 
overlayered with 1.1% NaCl (d = 1.006 g/ml) and centrifuged at 37,000g for 100 min at 4°C in a 
SW41 swinging bucket rotor (Beckman). The top 1.5 ml was collected. Chylomicron remnants 
were dialyzed against PBSA for 24 h. Remnant triacylglyercol was quantitated using the 
Triglyceride and Free Glycerol kit (Sigma-Aldrich); the amount of chylomicron remnant added 
is expressed as the µg amount of triacylglcyerol in the remnants. 100 µg of remnant 
triacylglycerol added to a plate of hepatocytes containing 3 ml of medium results in an amount of 
fatty acid equivalent to approximately 115 µM.  
Measurement of fatty acid synthesis  - The rate of de novo fatty acid synthesis was measured 
in primary rat hepatocytes using the tritiated water method (37). Cells were incubated with 0.2 
mCi/ml 3H2O during the last 3 h of a 24 h treatment with insulin (80 nM) and arachidonic acid 
(175 µm) or chylomicron remnants (100 µg). Incorporation of tritium into saponifiable lipids 
was determined as described (37).   
Statistics – Statistics were performed using GraphPad Prism (version 4.0). Overall statistical 
significance was determined by one-way ANOVA; multiple comparisons were made using a 
Bonferroni post-test if the overall p-value after ANOVA was p<0.05. 
  97 
 
RESULTS: 
 Chylomicron remnants were synthesized ex vivo by incubating purified chylomicrons 
with post-heparin plasma as a source of lipoprotein lipase.  Remnants prepared using this method 
acquire ApoC-II, to activate hepatic lipoprotein lipase, and Apo E, for clearance by the liver, 
from HDL present in the post-heparin plasma (38, 39).  Despite hydrolysis of the chylomicron 
triacylglycerol by plasma lipoprotein lipase, the remnant retains 15% to 30% of its 
triacylglycerol and the fatty acid composition of this triacylglycerol reflects the composition of 
the test meal and contributions from intestinal de novo fatty acid synthesis.   
 For collection of lymph, the rats were intubated intraduodenally with safflower oil or 
lard.  Safflower oil is unique amongst the vegetable oils in that it contains nearly all n6 
polyunsaturated fatty acid.  In contrast, lard is a mixed fat that is enriched in saturated fatty acids 
but can contain appreciable quantities of n6 and n3 polyunsaturated fatty acids 
(40)(Supplemental Table S2).  The total lipid content of the prepared chylomicron remnants was 
determined by gas chromatography (Fig. 1A).  Chylomicron remnants derived from rats 
intubated with safflower oil (polyunsaturated fatty acid-enriched remnants) contained 57.7% 
polyunsaturated fatty acids compared with only 21.3% polyunsaturated fatty acids in 
chylomicron remnants derived from rats intubated with lard (saturated fatty acid-enriched 
remnants).  The polyunsaturated fatty acids in both types of remnants were predominantly n6 
fatty acids (Fig. 1B).  As expected, saturated fatty acid-enriched chylomicron remnants contained 
twice the saturated fat content compared to polyunsaturated fatty acid-enriched chylomicron 
remnants (45.2% versus 21.2%).  These fatty acids were from the n9 family and their presence in 
polyunsaturated fatty acid-enriched chylomicron remnants likely represents fatty acids 
synthesized de novo by the intestine or were present in the bile phospholipid and absorbed into 
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the intestinal cell.  Thus, these two pools of chylomicron remnants have a similar fatty acid 
composition as the polyunsaturated- or saturated fat-enriched meals. 
 
 Free fatty acids stimulate multiple signaling kinases within hepatocytes.  Key amongst 
these are AMPK and the MAPKs (41-44).  In primary rat hepatocytes, incubation with albumin-
bound non-esterified arachidonic acid inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity 
and glucose-6-phosphate dehydrogenase (G6PD) mRNA expression through a p38 MAPK-
dependent mechanism (44); while docosahexaenoic acid, through modulations in the ERK 
signaling cascade, can affect transcription of lipogenic genes (45).  In order to determine what 
signaling molecules are activated by treatment with chylomicron remnants, primary hepatocytes 
were incubated with polyunsaturated fatty acid-enriched chylomicron remnants (100 µg 
triacylglycerol) or albumin-bound arachidonic acid (175 µM fatty acid) for 5, 10, and 30 min 
(Fig. 2A).  Treatment with 100 µg of remnant triacylglycerol (per plate of hepatocytes) results in 
a fatty acid concentration of approximately 115 µM.  These concentrations of polyunsaturated 
fatty acid-enriched chylomicron remnants and arachidonic acid result in maximal inhibition of 
G6PD expression (Supplementary Fig. 1)(46). Both non-esterified arachidonic acid and 
polyunsaturated fatty acid-enriched chylomicron remnants significantly increased p38 MAPK 
phosphorylation at 5 and 10 min; however, the increase in p38 MAPK phosphorylation was not 
observed after 30 min of incubation with polyunsaturated fatty acid-enriched chylomicron 
remnants.  In contrast, only albumin-bound arachidonic acid resulted in a sustained two-fold 
activation of ERK (Fig. 2B).  The increase in ERK phosphorylation at 5 min is observed 
regardless of treatment and likely reflects perturbation of the hepatocytes by the medium change.  
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Neither free fatty acid nor polyunsaturated fatty acid-enriched chylomicron remnants activated 
JNK (data not shown).   
 Free fatty acids are known to stimulate AMPK phosphorylation (41, 42).  Consistent with 
this, arachidonic acid caused an increase in AMPK phosphorylation.  The increase of 50% or 
more at 5 and 10 min of incubation, but by 30 min AMPK phosphorylation had decreased below 
no addition or insulin alone (Fig. 2A).  In contrast, polyunsaturated fatty acid-enriched 
chylomicron remnants did not result in a significant increase in AMPK phosphorylation but did 
result in the same drop in phosphorylation after 30 min of incubation (Fig. 2B). The reason for 
this drop is not clear but was consistently observed across experiments. 
 We next asked how treatment with polyunsaturated fatty acid-enriched chylomicron 
remnants would affect the insulin-signaling pathway and in particularly activation of PI3-kinase.  
Phosphorylation of AKT provides a reliable measure of PI3-kinase activation and changes in 
AKT phosphorylation by fatty acids reflect changes in PI3-kinase activity by direct 
measurements (44). In this regard, treatment with arachidonic acid inhibited AKT 
phosphorylation by approximately 45% at 5 minutes, and sustained this inhibition through 30 
minutes (Fig. 2A).  Treatment with polyunsaturated fatty acid-enriched chylomicron remnants 
does not inhibit AKT phosphorylation at any time point; the apparent decrease at 30 min was not 
significantly different from treatment with insulin alone (Fig. 2B). Extending the incubation of 
hepatocytes with polyunsaturated fatty acid-enriched chylomicron remnants for 60 and 90 
minutes does not result in an inhibition of AKT phosphorylation (data not shown).  
 IRS-1 phosphorylation is integral to maintenance of insulin responsiveness (47). 
Phosphorylation of IRS-1 at Tyr 608 and Tyr 628 by the insulin receptor forms docking sites for the 
regulatory subunit of PI3-kinase, and thus propagates the insulin signal. As expected, incubation 
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of hepatocytes for 60 minutes enhanced the tyrosine phosphorylation of IRS-1 (Fig. 2C).  
Albumin-bound arachidonic acid inhibited the insulin stimulation of tyrosine phosphorylation of 
IRS-1; however, incubation with polyunsaturated fatty acid-enriched chylomicron remnants did 
not inhibit the tyrosine phosphorylation of IRS-1 (Fig. 2C). 
 
 Phosphorylation of IRS-1 at Ser307, Ser612, and Ser632 uncouples IRS-1 from the insulin 
receptor and occludes the PI3-kinase binding sites (48, 49). Furthermore, serine phosphorylation 
at IRS-1 decreases the pool of IRS-1 available for tyrosine phosphorylation (50). We have shown 
previously that treatment of hepatocytes with arachidonic acid inhibits the insulin-signaling 
cascade through a decrease in AKT phosphorylation coincident with IRS-1 serine 
phosphorylation (44). To test if polyunsaturated fatty acid-enriched chylomicron remnants share 
this mechanism, hepatocytes were incubated with polyunsaturated fatty acid-enriched 
chylomicron remnants or arachidonic acid for 60 minutes (Fig. 2C). As expected, arachidonic 
acid treatment increases IRS-1ser307 phosphorylation by almost 3-fold, whereas polyunsaturated 
fatty acid-enriched chylomicron remnant treatment did not increase IRS-1ser307 phosphorylation 
above treatment with insulin alone. Thus, polyunsaturated fatty acid-enriched chylomicron 
remnants do not result in the down-regulation of insulin signaling that is observed with free fatty 
acids. 
 Providing polyunsaturated fatty acid to hepatocytes as chylomicron remnants, the manner 
in which dietary fat reaches the liver, results in discrete differences in the activation and 
inhibition of signal transduction pathways within the liver.  We next asked if these signaling 
differences resulted in differential effects of albumin-bound fatty acids and chylomicron 
remnants on hepatic lipogenesis.  The rate of de novo fatty acid synthesis was measured by 
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calculating the incorporation of 3H2O into saponifiable lipid. Insulin enhanced the rate of de 
novo fatty acid synthesis by 3.5-fold (Fig. 3). Addition of either arachidonic acid or chylomicron 
remnants inhibited lipogenic rate by 50%. The hallmark of the regulation of fatty acid synthesis 
is that inhibition by dietary fat is specific for polyunsaturated fat of the n6 and n3 families and 
does not occur following consumption of saturated fat (13, 18). Treatment of hepatocytes with 
saturated fat-enriched chylomicron remnants does not inhibit the insulin stimulation of fatty acid 
synthesis. Thus, regulation of lipogenic rate by polyunsaturated fatty acid- and saturated fatty 
acid-enriched chylomicron remnants is consistent with regulation by dietary fat in intact liver.  
Because lipogenic rate was measured during the last 3 h of a 24 h incubation with the remnants 
or arachidonic acid, the decrease in rate is likely caused by a combination of short term 
regulation of pacesetting enzymes, such as acetyl-CoA carboxylase, and inhibition of the 
expression genes for the lipogenic enzymes. 
 G6PD has been a useful prototype for studying regulation of lipogenic enzymes because 
its expression is stimulated by insulin and inhibited by polyunsaturated fatty acid, in the absence 
of other hormones such as glucocorticoids or thyroid hormone that could confound the 
interpretation of the results.  Dietary polyunsaturated fatty acid causes a rapid inhibition of 
G6PD expression; a decrease in mRNA accumulation is detected within 4 h of starting a 
polyunsaturated fatty acid containing diet and is maximal by 8 h (46). This time is consistent 
with the appearance of high concentrations of chylomicron remnants in the blood (51).  In 
primary hepatocytes, arachidonic acid inhibition of G6PD mRNA accumulation follows a similar 
time course (Fig. 4A)(33).  Incubation with a maximally inhibitory concentration of 
polyunsaturated fatty acid (Supplemental Fig. S1) also results in a significant inhibition of G6PD 
mRNA expression (Fig. 4A). This inhibition is observed by 4 h and continues through 24 h.  
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 The inhibition by polyunsaturated fatty acid requires the presence of insulin, which 
induces G6PD expression (44). In this regard, insulin stimulated G6PD mRNA accumulation by 
3-fold and polyunsaturated fatty acid-enriched chylomicron remnants inhibited this accumulation 
by 45% or more (Fig. 4B). Polyunsaturated fatty acid-enriched chylomicron remnants in the 
absence of insulin have no effect on G6PD expression. Since safflower oil contains 
approximately 78% linoleic acid (Supplemental Table S2), we compared the effect of non-
esterified linoleic acid, as well as the longer chain fatty acids, arachidonic acid and 
eicosapentaenoic acid, to the effect of polyunsaturated fatty acid-enriched chylomicron remnants.  
Non-esterified polyunsaturated fatty acids (arachidonic acid, linoleic acid, and eicosapentaenoic 
acid) inhibit this stimulation by 45-60%, similar to the extent of inhibition by polyunsaturated 
fatty acid-enriched chylomicron remnants. Furthermore, inhibition by chylomicron remnants was 
specific for polyunsaturated fatty acid-enriched chylomicron remnants; treatment with the 
saturated fatty acid-enriched chylomicron remnants did not inhibit G6PD. Thus, the small 
amounts of n6 polyunsaturated fatty acids in saturated fatty acid-enriched chylomicron remnants 
were insufficient to inhibit G6PD expression. We also treated hepatocytes with nascent 
chylomicrons, which are excluded from uptake by hepatocytes due to their large size and lack of 
ApoE for recognition by cell surface receptors. Treatment with either polyunsaturated fatty acid- 
or saturated fatty acid-enriched chylomicrons did not inhibit G6PD mRNA expression. Thus, the 
polyunsaturated fatty acid-enriched chylomicron remnants inhibition of G6PD expression is 
consistent with chylomicron remnants as a mediator of dietary fat effects on the liver.  
 Regulation of G6PD expression by dietary fat occurs exclusively at a posttranscriptional 
step.  We next asked if the inhibitory effect of polyunsaturated fatty acid-enriched chylomicron 
remnants would extend to other lipogenic genes. Polyunsaturated fatty acids of the n3 and n6 
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families are well-established suppressors of SREBP-1c activity, either as non-esterified fatty 
acids or as part of the diet (52, 53). Therefore, we asked whether polyunsaturated fatty acid-
enriched chylomicron remnants would inhibit the expression of SREBP-1c mRNA (Fig. 5A).  
The addition of insulin increased SREBP-1c mRNA expression by 3-fold. Addition of 
arachidonic acid, eicosapentaenoic acid or linoleic acid inhibited this increase 64% or more. 
Polyunsaturated fatty acid-enriched chylomicron remnants also inhibited the insulin induction of 
SREBP-1c mRNA by 60%. Saturated fatty acid-enriched chylomicron remnants had no effect on 
SREBP-1c mRNA expression. Treatment with nascent chylomicrons or remnants alone did not 
affect SREBP-1c mRNA abundance. The activity of SREBP-1c as a transcription factor requires 
its cleavage by specific proteases and thereby release from intracellular membranes (54).  
Release of active or mature SREBP-1c is also inhibited by polyunsaturated fatty acid (Fig. 
5B)(55, 56). Treatment with polyunsaturated fatty acid-enriched chylomicron remnants resulted 
in a similar decrease in mature SREBP-1c production as observed with non-esterified 
arachidonic acid whereas treatment with saturated fatty acid-enriched chylomicron remnants or 
nascent chylomicrons did not inhibit mature SREBP-1c protein formation. Therefore, 
polyunsaturated fatty acid-enriched chylomicron remnants mimic the effect of dietary 
polyunsaturated fatty acids on SREBP-1c expression and activity. 
 Fatty acid synthase, acetyl-CoA carboxylase-1, stearoyl-CoA desaturase 1, ATP-citrate 
lyase, and S14 are SREBP-1c target genes. Changes in SREBP-1c activity should therefore 
regulate these genes in parallel.  Insulin increased the expression of these genes. These 
hepatocytes only received insulin; therefore this induction is less than what was seen in some 
reports in which the medium was supplemented with additional hormones (57). Polyunsaturated 
fatty acid-enriched chylomicron remnants significantly inhibited the expression of fatty acid 
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synthase, acetyl-CoA carboxylase-1, stearoyl-CoA desaturase 1, ATP-citrate lyase, and S14 
mRNAs and the magnitude of this decrease is the same as that observed with the non-esterified 
fatty acids (Fig. 6). These results are in parallel to the changes in the amount of mature SREBP-
1c or SREBP-1c mRNA. Saturated fatty acid-enriched chylomicron remnants did not inhibit 
expression of fatty acid synthase, acetyl-CoA carboxylase-1, or stearoyl-CoA desaturase 1. A 
small decrease was observed in the expression of ATP-citrate lyase and S14 following treatment 
with saturated fatty acid-enriched chylomicron remnants and this may be due to the minor 
amounts of n6 fatty acids in these particles.  Because saturated fatty acid-enriched chylomicron 
remnants do not inhibit SREBP-1c expression or maturation, the effect of saturated fatty acid-
enriched chylomicron remnants on ATP-citrate lyase and S14 must involve pathways distinct 
from the other SREBP-1c targets.   
  In addition to the lipogenic enzymes, genes in the glycolytic (glucokinase and L-
pyruvate kinase) and bile acid synthetic (Cyp-7α) pathways are also coordinately regulated by 
polyunsaturated fatty acid. Inhibition of these genes by polyunsaturated fatty acid does not 
involve SREBP-1c but uses transcription factors including the carbohydrate response element 
binding protein (ChREBP) and the liver X receptor (LXR). Malic enzyme, a lipogenic enzyme, 
was also examined because like G6PD, its regulation does not appear to directly involve SREBP-
1c and may also be regulated at posttranscriptional steps (58).  Expression of each of these genes 
was enhanced by insulin and significantly inhibited by albumin bound polyunsaturated fatty 
acids (Fig. 7).  In contrast, polyunsaturated fatty acid-enriched chylomicron remnants did not 
significantly inhibit the mRNA expression of malic enzyme, L-pyruvate kinase, or Cyp-7α 
compared to treatment with insulin. As each of these enzymes is inhibited by dietary 
  105 
 
polyunsaturated fatty acid, the mechanism for inhibition in intact animals must involve another 
dietary-derived humoral factor.  
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DISCUSSION: 
 Primary rat hepatocytes in culture have provided the best model system to decipher the 
mechanisms by which dietary fat regulates hepatic metabolism and lipogenic gene expression.  
Compared to liver cell lines, hepatocytes in primary culture retain more liver-specific traits and 
the components of the signaling pathways involved in regulating liver-specific gene expression 
(18).  In the intact animal, the liver is exposed to fatty acids in two distinct ways: dietary (or 
exogenous) fatty acids in the form of triacylglycerols are delivered to the liver in chylomicron 
remnants, and adipose-derived (endogenous) non-esterified fatty acids are presented to the liver 
bound to serum albumin in a non-covalent manner. Yet, to model regulation of liver metabolism 
by dietary fat, primary rat hepatocytes have traditionally been incubated with albumin bound 
non-esterified fatty acids. While a facile treatment method, it does not duplicate the presentation 
of dietary fatty acids, which occurs via chylomicron remnants. Treatment of hepatocytes with 
non-esterified fatty acids presumes that the regulatory effects of polyunsaturated fatty acids, 
regardless of source, occur via an increase in intracellular fatty acid concentration, an untested 
assumption. Primary hepatocytes in culture express functioning versions of the necessary 
receptors and cell-surface molecules for chylomicron remnant uptake and thus, their regulatory 
potential can be measured (59). In the present report we measured the regulatory actions of 
chylomicron remnants as a model for the effects of dietary polyunsaturated fatty acids on the 
liver. 
 Polyunsaturated fatty acid-enriched chylomicron remnants inhibit both the rate of hepatic 
fatty acid synthesis (Fig. 3) and expression of the lipogenic genes SREBP-1c, fatty acid synthase, 
acetyl-CoA carboxylase, stearoyl-CoA desaturase 1, ATP-citrate lyase, and S14 (Figs. 4-6). In 
this regard, the regulatory potential of polyunsaturated fatty acid-enriched chylomicron remnants 
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is similar to regulation by non-esterified polyunsaturated fatty acids. The inhibition of 
lipogenesis was specific for remnants derived from polyunsaturated dietary lipids; saturated fat-
enriched chylomicron remnants did not inhibit lipogenic rate or expression of the lipogenic 
genes. This comparison is not possible with non-esterified fatty acids; the toxicity of palmitate 
and stearate in primary hepatocytes confounds the interpretation of these results (18, 19). Thus 
the differential inhibitory effects of dietary polyunsaturated fatty acids versus saturated fatty 
acids are recapitulated by incubation of primary hepatocytes with chylomicron remnants derived 
from different fats and these effects appear to be mediated by regulatory events within the liver 
cell.  
 In contrast to genes of the lipogenic pathway, remnants do not inhibit the accumulation of 
mRNA for glucokinase, L-pyruvate kinase, Cyp-7α, and malic enzyme, although these genes are 
inhibited by non-esterified polyunsaturated fatty acids (Fig. 7).  Accompanying this difference, 
polyunsaturated fatty acid-enriched chylomicron remnants and non-esterified polyunsaturated 
fatty acids do not stimulate the same intracellular signaling pathways (Fig. 2).  In contrast to non-
esterified polyunsaturated fatty acids, polyunsaturated fatty acid-enriched chylomicron remnants 
do not decrease insulin signaling to AKT nor do they activate AMPK or ERK. While lipids from 
both sources activate p38 MAPK, the activation is sustained in cells incubated with non-
esterified fatty acid but disappears by 30 min in hepatocytes incubated with chylomicron 
remnants (Fig. 2A).  
 The inhibition of SREBP-1c dependent genes by polyunsaturated fatty acid-enriched 
chylomicron remnants appears to be mediated by changes in SREBP-1c activity (Fig. 5) and this 
is consistent with this being the mechanisms for inhibition of these genes by dietary fat (10, 56, 
57, 60, 61). The lack of effect of polyunsaturated fatty acid-enriched chylomicron remnants on 
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SREBP-1c independent genes may involve differences between remnant and non-esterified fatty 
acids in decreasing insulin signal transduction (Fig. 2)(44).  Expression of glucokinase and malic 
enzyme are highly dependent on stimulation by insulin (62). L-pyruvate kinase expression is not 
directly stimulated by insulin, but its stimulation by a glucose-derived metabolite requires 
glucokinase activity and thus, indirectly, insulin action (63).  An alternative possibility for this 
difference between genes is that fatty acids from polyunsaturated fatty acid-enriched 
chylomicron remnants may be oxidized or metabolized more quickly than non-esterified 
polyunsaturated fatty acids, such that the intracellular concentration of fatty acid or relevant 
metabolite necessary for inhibition of SREBP-1c independent genes may only be achieved with 
non-esterified polyunsaturated fatty acids.  The decrease in p38 MAPK activation by 30 min of 
chylomicron remnant treatment is consistent with this possibility (Fig. 2B).  In contrast to 
transcriptionally regulated enzymes, G6PD is not transcriptionally regulated and inhibition of 
G6PD mRNA accumulation by both polyunsaturated fatty acid-enriched chylomicron remnants 
and non-esterified fatty acids indicates additional potential mechanisms that do not involve 
transcription factors.  
From the perspective of identifying intracellular signaling pathways, incubation of 
primary rat hepatocytes with non-esterified fatty acids appear to be a better model of the starved 
state or uncontrolled diabetes than a model for regulation by dietary fat.  In intact animals, free 
fatty acids concentrations in blood rise sharply during stimulated lipolysis, a hallmark of 
starvation. In this regard, the fatty acid activation of p38 MAPK and the inhibition of AKT 
activation and Tyr-phosphorylation of IRS-1 are observed with both non-esterified fatty acids in 
primary hepatocytes and in liver during diabetes (Fig. 2)(44, 64).  This suggests that fatty 
signaling and not just hormonal signaling is involved in the metabolic shift toward glucose 
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production and away from glycolytic flux and lipogenesis.  In the fed state, dietary 
polyunsaturated fatty acids (presented as triacylglycerols in chylomicron remnants) play a role in 
long-term adaptation to nutritional status by inhibiting the capacity of the liver to synthesize fatty 
acids de novo.  The signaling cascades involved do not appear to involve sustained changes in 
insulin signal transduction but appear to interact with alternative machinery within the cell such 
as the activity of the lipogenic transcription factor, SREBP-1c.  
Thus mode of presentation of lipid to the liver is a determinant of its intracellular action.  
Internalization of remnant triacylglycerol involves remnant binding to cell surface heparan 
sulfate proteoglycans and the LDL receptor (LDLR) or the LDLR-related protein (LRP)(65-68).  
Uptake of the remnant fatty acid can occur by both hepatic lipase hydrolysis on the extracellular 
surface and lysosomal digestion of the internalized remnant particle (69). Albumin-bound non-
esterified fatty acids enter the hepatocyte through disassociation from albumin at the 
extracellular surface and either diffusion into the cell or entry via fatty acid transport proteins 
(70). 
 Several lines of evidence indicate that mode of uptake will alter intracellular metabolism of 
fatty acids.  Although the acyl groups from dietary triacylglycerol and adipose-derived non-
esterified fatty acids are not chemically distinct, uptake appears to be coupled to different 
intracellular enzymes, such as distinct fatty acid transport proteins (FATP) and acyl-CoA 
synthetases (ACS). When polyunsaturated fatty acids are activated by ACS4 they become 
preferentially destined for peroxisomal oxidation, rather than a substrate for other intracellular 
metabolic pathways (71-73). Fatty acid uptake mediated by FATP5, however, causes fatty acids 
to be shunted toward de novo triacylglycerol synthesis (31). The primary fate of fatty acids 
derived from remnant uptake is not known, although they can be incorporated into intracellular 
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lipids and oxidized by beta-oxidation (74). Fatty acids derived from hydrolysis of internal 
triacylglycerol stores preferentially activate PPAR-alpha in liver and therefore function in an 
intracellular signaling pathway (75). Triacylglycerol derived from remnants may share this 
mechanism.  It is tempting to speculate that differences in the regulatory actions of non-esterified 
polyunsaturated fatty acids and chylomicron remnant derived fatty acids are due to these 
differences in metabolic partitioning. 
 Therefore, incubation of primary hepatocytes with non-esterified polyunsaturated fatty 
acids represents a different paradigm than regulation of liver metabolism by dietary 
polyunsaturated fatty acids.  While some effects of dietary fat as modeled with chylomicron 
remnants are recapitulated by non-esterified polyunsaturated fatty acids, albumin-bound fatty 
acids represent an important mechanism of energy delivery in the starved state and in 
uncontrolled diabetes mellitus.  Furthermore, the inhibition of insulin signal transduction by non-
esterified polyunsaturated fatty acids resembles the insulin resistant state of the liver during 
adaptation to prolonged feeding of a high-fat diet.  In contrast, polyunsaturated fatty acid-
enriched chylomicron remnants do not decrease insulin signaling suggesting that the decrease in 
lipogenic rate and capacity involve separate mechanisms. Thus, the method of lipid delivery to 
hepatocytes is an important consideration in deciphering mechanisms involved in transduction of 
dietary fat signals within the liver. 
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ABBREVIATIONS: 
ACS, acyl-CoA synthetase; AMPK, AMP activated protein kinase; Apo, apolipoprotein; 
ChREBP, carbohydrate response element binding protein; Cyp7a, cytochrome P450 7a; ERK, 
extracellular-signaling kinase; FATP, fatty acid transport protein; G6PD, glucose-6-phosphate 
dehydrogenase; IRS, insulin receptor substrate; LDLR, LDL receptor; LRP1, LDL receptor 
related protein 1; LXR, liver X receptor; MAPK, mitogen activated protein kinase; PI3-kinase, 
phosphatidylinositol 3-kinase; SREBP-1c, sterol response element binding protein-1c 
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FIGURE LEGENDS: 
 
Figure 1. Chylomicron remnants from rats intubated with safflower oil are enriched in 
polyunsaturated fatty acid. Total lipid analysis was performed by Lipomics Technologies 
(Sacramento, CA) to determine the fatty acid composition of the prepared chylomicron remnants. 
Data is expressed as the percent of the total triacylglycerol content of the chylomicron remnants. 
A. Gray bars represent chylomicron remnants derived from safflower oil-intubated rats; black 
bars represent chylomicron remnants derived from lard-intubated rats. B. The polyunsaturated 
fatty acid species making up the total chylomicron remnant triacylglycerol were determined as in 
A. n3, n6, n7, n9 refers to the position of the double bond from the methyl end of the fatty acid. 
SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; 
CR, chylomicron remnants; TAG, triacylglycerol. 
 
Figure 2.  Polyunsaturated fatty acid-enriched chylomicron remnants and non-esterified 
polyunsaturated fatty acids result in different patterns of cellular signaling.  Primary rat 
hepatocytes were plated on collagen coated dishes and incubated in Hi/Wo/Ba medium.  After 20 
h in culture, the medium was replaced with Hi/Wo/Ba with or without insulin (80 nM; I), 
albumin-bound arachidonic acid (175 µM; AA), or polyunsaturated fatty acid-enriched 
chylomicron remnants (100 µg triacylglycerol; PUFA CR). For measurement of AMPK and p38 
MAPK, the cells (2 plates/treatment) were harvested and total cell lysates prepared at 5, 10 and 
30 min after treatment.  AKT and ERK were measured in cells (2 plates/treatment) incubated 
with or without albumin-bound arachidonic acid (175 µM), or polyunsaturated fatty acid-
enriched chylomicron remnants (100 µg triacylglycerol) for 24 h and then treated with insulin 
(80 nM) for 5, 10 and 30 min.  A. Western analysis was performed using antibodies against 
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phosphorylated Thr180/ Tyr182 of p38 MAPK, Thr202/Tyr204 of ERK, Thr172 of AMPK, and Ser473 
of AKT, as well as against the total amount of each protein.  Representative blots are shown.  B. 
Quantitative representation of the fold increase in phosphorylated protein as compared to no 
addition (NA) at each time point. Densitometry was performed with ImageQuant software 
(Molecular Dynamics). Values were calculated as arbitrary densitometric units of 
phosphorylated protein divided by total protein and are expressed as the fold-increase over no 
addition (NA). Each bar represents the mean and SE of n=4 separate hepatocyte isolations. (*) 
p<0.05 compared to cells treated with insulin. C. For measurement of IRS-1, the cells (3 
plates/treatment) were harvested and total cell lysates prepared 60 min after treatment. For 
phosphorylated IRS-1, immunoprecipitation was performed using an antibody against total IRS-
1 followed by western analysis using an antibody against Ser307 of IRS-1 (right graph) or 
phosho-tyrosine (left graph). Total IRS-1 was measured by western analysis using an antibody 
against total IRS-1. Densitometry is expressed at arbitrary densitometric units and is a measure 
of phosphorylated protein divided by total protein. Each bar represents the mean and SE of n=4 
separate hepatocyte isolations. (*) p<0.05 compared to cells treated with insulin, NS, not 
significant.  
 
Figure 3. Polyunsaturated fatty acid-enriched chylomicron remnants inhibit the rate of 
fatty acid synthesis. Primary rat hepatocytes were plated on collagen coated dishes and 
incubated in Hi/Wo/Ba medium.  After 20 h in culture, the medium was replaced with Hi/Wo/Ba 
with or without insulin (80 nM; I), albumin-bound arachidonic acid (175 µM; AA), or 
chylomicron remnants (100 µg triacylglycerol; CR). Media was replaced every 12 h with one of 
identical composition, and fatty acid synthesis was measured after 24 h of treatment as described 
  123 
 
in the methods (3 plates/treatment). Values are expressed as the fold-increase over no addition 
(NA). Each bar represents the mean ± SE of n=3 independent primary hepatocyte isolations. (*) 
p<0.05 compared to cells treated with insulin, NS, not significant. NA, no addition; I, insulin; 
AA, arachidonic acid; PUFA CR, polyunsaturated fatty acid-enriched chylomicron remnants; 
LARD CR, saturated fatty acid-enriched chylomicron remnants.  
 
Figure 4. G6PD expression is inhibited by both polyunsaturated fatty acid-enriched 
chylomicron remnants and non-esterified polyunsaturated fatty acids. Primary rat 
hepatocytes were plated on collagen coated dishes and incubated in Hi/Wo/Ba medium.  A. After 
20 h in culture, the medium was replaced with Hi/Wo/Ba with insulin (80 nM; I) for 24 h. 
Albumin-bound arachidonic acid (175 µM; AA-solid line), or polyunsaturated fatty acid-
enriched chylomicron remnants (100 µg triacylglycerol; PUFA CR-dashed line) were then added 
to the media and RNA was isolated after 0, 2, 4, 8, and 24 h (2 plates/treatment). RNA 
expression was determined by quantitative real-time RT-PCR relative to rat cyclophilin B. 
Values are expressed compared to cells treated with insulin. Each bar represents the mean ± SE 
of n=3 independent primary hepatocyte isolations. B. Primary rat hepatocytes were incubated 
with Hi/Wo/Ba with or without insulin (80 nM; I), albumin-bound fatty acid (175 µM; AA, EPA, 
LIN), chylomicron remnants (100 µg triacylglycerol; CR), or chylomicrons (100 µg 
triacylglycerol; CM). Media was replaced every 12 h with one of identical composition, and 
RNA was isolated after 24 h with treatment (2 plates/treatment). RNA expression was 
determined by quantitative real-time RT-PCR relative to rat cyclophilin B. Values are expressed 
as the fold-increase over no addition (NA). (*) p<0.05, compared to cells treated with insulin, 
NS, not significant. Each bar represents the mean ± SE of the indicated number of independent 
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primary hepatocyte isolations: NA, INS, AA, n=8; EPA, LIN, n=5; PUFA CR, LARD CR, 
PUFA CM, LARD CM, n=8. G6PD, glucose-6-phosphate dehydrogenase; NA, no addition; I, 
insulin; AA, arachidonic acid; EPA, eicosapentaenoic acid; LIN, linoleic acid; PUFA CR, 
polyunsaturated fatty acid-enriched chylomicron remnants; LARD CR, saturated fatty acid-
enriched chylomicron remnants; PUFA CM, polyunsaturated fatty acid-enriched chylomicrons; 
LARD CM, saturated fatty acid-enriched chylomicrons.  
 
Figure 5. SREBP-1c is inhibited by polyunsaturated fatty acid-enriched chylomicron 
remnants. Primary rat hepatocytes were plated on collagen coated dishes and incubated in 
Hi/Wo/Ba medium. After 20 h in culture, the medium was replaced with Hi/Wo/Ba with or 
without insulin (80 nM; I), albumin-bound fatty acid (175 µM; AA, EPA, LIN), chylomicron 
remnants (100 µg triacylglycerol; CR), or chylomicrons (100 µg triacylglycerol; CM). Media 
was replaced every 12 h with one of identical composition. A. RNA was isolated after 24 h in 
culture (2 plates/treatment). RNA expression was determined by quantitative real-time RT-PCR 
relative to rat cyclophilin B. Values are expressed as the fold-increase over no addition (NA). (*) 
p<0.05, compared to cells treated with insulin, NS, not significant. Each bar represents the mean 
± SE of the indicated number of independent primary hepatocyte isolations:  NA, INS, AA, n=8; 
EPA, LIN, n=3; PUFA CR, n=6; LARD CR, PUFA CM, LARD CM, n=3. B. For measurement 
of mature SREBP-1c, cells were harvested and total cell lysates prepared 30 min after treatment 
(2 plates/treatment).  Western analysis was performed using an antibody against total SREBP-1c 
(Santa Cruz). A representative blot is shown. Densitometry was performed with ImageQuant 
software (Molecular Dynamics), and values were calculated as arbitrary densitometric units of 
mature protein. (*) p<0.05 compared to cells treated with insulin. Each bar represents the mean ± 
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SE of n=3 independent primary hepatocyte isolations. SREBP-1c, sterol regulatory element 
binding protein-1c; NA, no addition; AA, arachidonic acid; EPA, eicosapentaenoic acid; LIN, 
linoleic acid; PUFA CR, polyunsaturated fatty acid-enriched chylomicron remnants; LARD CR, 
saturated fatty acid-enriched chylomicron remnants; PUFA CM, polyunsaturated fatty acid-
enriched chylomicrons; LARD CM, saturated fatty acid-enriched chylomicrons.  
 
Figure 6. Polyunsaturated fatty acid-enriched chylomicron remnants inhibit the expression 
of SREBP-1c dependent genes. Primary rat hepatocytes were plated on collagen coated dishes 
and incubated in Hi/Wo/Ba medium. After 20 h in culture, the medium was replaced with 
Hi/Wo/Ba with or without insulin (80 nM; I), albumin-bound fatty acid (175 µM; AA, EPA, 
LIN), chylomicron remnants (100 µg triacylglycerol; CR), or chylomicrons (100 µg 
triacylglycerol; CM). Media was replaced every 12 h with one of identical composition, and 
RNA was isolated after 24 h of treatment (2 plates/treatment). RNA expression was determined 
by quantitative real-time RT-PCR relative to rat cyclophilin B. Values are expressed as the fold-
increase over no addition (NA). (*) p<0.05, compared to cells treated with insulin, NS, not 
significant. Each bar represents the mean ± SE of the indicated number of independent primary 
hepatocyte isolations:  NA, INS, AA, n=8; EPA, LIN, n=5; PUFA CR, LARD CR, n=8; PUFA 
CM, LARD CM, n=6. FAS, fatty acid synthase; ACC-1, acetyl-CoA carboxylase-1; ATP-CL, 
ATP-citrate lyase; SCD, stearoyl -CoA desaturase 1; S14, spot 14; NA, no addition; AA, 
arachidonic acid; EPA, eicosapentaenoic acid; LIN, linoleic acid; PUFA CR, polyunsaturated 
fatty acid-enriched chylomicron remnants; LARD CR, saturated fatty acid-enriched chylomicron 
remnants; PUFA CM, polyunsaturated fatty acid-enriched chylomicrons; LARD CM, saturated 
fatty acid-enriched chylomicrons.  
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Figure 7. PUFA-enriched chylomicron remnants do not inhibit the expression of SREBP-1c 
independent genes. Primary rat hepatocytes were plated on collagen coated dishes and 
incubated in Hi/Wo/Ba medium. After 20 h in culture, the medium was replaced with Hi/Wo/Ba 
with or without insulin (80 nM; I), albumin-bound fatty acid (175 µM; AA, EPA, LIN), 
chylomicron remnants (100 µg triacylglycerol; CR), or chylomicrons (100 µg triacylglycerol; 
CM). Media was replaced every 12 h with one of identical composition, and RNA was isolated 
after 24 h with treatment (2 plates/treatment). RNA expression was determined by quantitative 
real-time RT-PCR relative to rat cyclophilin B. Values are expressed as the fold-increase over no 
addition (NA). (*) p<0.05, compared to cells treated with insulin, NS, not significant. Each bar 
represents the mean ± SE of the indicated number of independent primary hepatocyte isolations:  
NA, INS, AA, n=8; EPA, LIN, n=5; PUFA CR, LARD CR, n=8; PUFA CM, LARD CM, n=6. 
GK, glucokinase; Cyp-7α, cytochrome p450-7a; ME, malic enzyme; L-PK, liver pyruvate 
kinase; NA, no addition; AA, arachidonic acid; EPA, eicosapentaenoic acid; LIN, linoleic acid; 
PUFA CR, polyunsaturated fatty acid-enriched chylomicron remnants; LARD CR, saturated 
fatty acid-enriched chylomicron remnants; PUFA CM, polyunsaturated fatty acid-enriched 
chylomicrons; LARD CM, saturated fatty acid-enriched chylomicrons.  
 
Supplemental Figure S1.  Primary rat hepatocytes were plated on collagen coated dishes and 
incubated in Hi/Wo/Ba medium. After 20 h in culture, the medium was replaced with Hi/Wo/Ba 
with insulin (80 nM; I) and polyunsaturated fatty acid-enriched chylomicron remnants (25-100 
µg triacylglycerol; PUFA CR). Media was replaced every 12 h with one of identical 
composition, and RNA was isolated after 24 h with treatment (2 plates/treatment). RNA 
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expression was determined by quantitative real-time RT-PCR relative to rat cyclophilin B. 
Values are expressed compared to treatment with insulin. Each bar represents the mean ± SE of 
n=3 independent primary hepatocyte isolations. G6PD, glucose-6-phosphate dehydrogenase. 
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Supplemental Table S1. Primers Used in Quantitative RT-PCR Analysis. Primers to rat 
mRNA sequences were designed and synthesized using PrimerQuest (Integrated DNA 
Technologies). The specificity of primers was verified by BLAST analysis, visualization of RT-
PCR products by ethidium bromide staining after agarose gel electrophoresis, and by melt curve 
analysis of PCR products. 
 mRNA       Primers 
Acetyl-CoA carboxylase-1   sense, 5'-AGGGCAAAGGGACTGGTGTTCAGAT-3' 
     antisense, 5'-GCCAACGGAGATGGTTCATCCATTA-3' 
 
ATP-citrate lyase   sense,  5’-TGGTTTCATCGGCGTTGCGTTT -3’     
 antisense, 5’-TTGGCTTTCCATGCCTGCACAT-3’ 
 
Cyclophilin B    sense, 5'-CGTGGGCTCCGTTGTCTT-3' 
      antisense, 5'-TGACTTTAGGTCCCTTCTTCTTATC 
 
Cyp7a sense, 5’-CCTTTGGAGAACGGGTTGATT-3’ 
 antisense, 5’-CAGGGAGTTTGTGATGAAATGG-3’    
 
Fatty acid synthase    sense, 5'-TGCAACTGTGCGTTAGCCACC-3' 
     antisense, 5'-TGTTTCAGGGGAGAAGAGACC-3'  
 
Glucokinase     sense, 5'-GGAGACTTTCTCTCCTTAAGAC-3' 
     antisense, 5'-ATTGGCGGTCTTCATAGTAGC-3' 
 
Glucose 6-phosphate   sense, 5'-TATGTCTATGGCAGCCGAGGT-3'  
dehydrogenase   antisense, 5'- GCAGAGTGCAGATGGTGTAAG -3' 
 
Malic enzyme    sense, 5'-TTGTTGCCACCCTGCATTGTCA-3' 
     antisense, 5'-ACAACATCTTCTGGCCATGCGT-3' 
 
Pyruvate kinase, liver   sense, 5'-GATGAAATTCTAGAAG-3' 
     antisense, 5'-GCTTCGTCAGCACGATG-3' 
 
Spot-14     sense, 5'-CAGGAGGTGACGCAGAAATAC-3' 
     antisense, 5'-GTGAGGTAAATACAGCGTCCC-3' 
 
Stearoyl-CoA desaturase-1   sense, 5'-AGCTCAGCCAAATGCTGTGTTGTC-3' 
     antisense, 5'-TGCCTTGATCAGTCACAGACACCT-3' 
 
Sterol regulatory element   sense, 5'-ACGACGGAGCCATGGATTGCAC-3'  
binding protein-1c    antisense, 5'-CCGGAAGGCAGGCTTGAGTACC-3' 
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Supplemental Table S2.  Fatty acid composition of safflower oil and lard.  Approximate 
composition of these dietary fats are reproduced here from a published source (40).   
        
Fatty Acid Safflower Oil  Lard  
   % of total fatty acids         
4-10:0      0.1 
12:0      0.1 
14:0   0.1   1.5 
16:0   6.5   24.8 
16:1      3.1 
18:0   2.4   12.3 
18:1   13.1   45.1 
18:2   77.7   9.9 
18:3      1.1 
other   0.2   3.0  
 
 
 
  139 
 
APPENDIX. 
 
Figure 1. Effect of chylomicron remnants on potential PPAR-a target genes. Primary rat 
hepatocytes were plated on collagen-coated plates in Hi/Wo/Ba medium supplemented with 5% 
newborn calf serum. 2 h later, the medium was removed and hepatocytes received Matrigel® in 
serum-free Hi/Wo/Ba medium. 20 h after plating, medium was replaced (without Matrigel) and 
hepatocytes were treated with or without 80 nM insulin, 175 mM arachidonic acid, 
eicosapentaenoic acid (EPA), linoleic acid (LIN), or 100 µg chylomicron remnants (CR) or 
chylomicrons (CM). Media was replaced every 12 h complete with treatments, and RNA was 
isolated after 24 h in culture.  RNA expression was determined by quantitative Real Time RT-
PCR, and is expressed relative to rat cyclophilin B.  Each bar represents the mean ± SE of n=4 
independent primary hepatocyte isolations, with the exception of eicosapentaenoic and linoleic 
acid treatments, where n=2.  
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Figure 2. Effect of chylomicron remnants on PPAR-a target genes. Primary rat hepatocytes 
were plated on collagen-coated plates in Hi/Wo/Ba medium supplemented with 5% newborn calf 
serum. 2 h later, the medium was removed and hepatocytes received Matrigel® in serum-free 
Hi/Wo/Ba medium. 20 h after plating, medium was replaced (without Matrigel) and hepatocytes 
were treated with or without 80 nM insulin, 175 mM arachidonic acid, eicosapentaenoic acid 
(EPA), linoleic acid (LIN), or 100 µg chylomicron remnants (CR) or chylomicrons (CM). Media 
was replaced every 12 h complete with treatments, and RNA was isolated after 24 h in culture.  
RNA expression was determined by quantitative Real Time RT-PCR, and is expressed relative to 
rat cyclophilin B.  Each bar represents the mean ± SE of n=4 independent primary hepatocyte 
isolations.  
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Figure 3.  Effect of constitutively-active AKT on lipogenic mRNA. Primary rat hepatocytes 
were plated on collagen coated dishes and incubated in Hi/Wo/Ba medium. After 2 h in culture, 
hepatocytes were infected with 1, 5, and 10 infectious units/cell of either constitutively-active 
AKT expressing adenovirus (CA-AKT) or control adenovirus expressing GFP. After 2 h, cells 
were washed twice, and media was replaced with one containing Matrigel. After 20 h in culture, 
the medium was replaced with Hi/Wo/Ba with or without insulin (40 nM; I) and arachidonic acid 
(175 µM; AA).  For isolation of mRNA, media was replaced every 12 h with one of identical 
composition, and RNA was isolated after 24 h of treatment (2 plates/treatment). G6PD mRNA 
abundance is calculated relative to rat cyclophilin B. Values are expressed as the fold-increase 
over no addition (NA). Each bar represents the mean ± SE of n=3 independent primary 
hepatocyte isolations.  
 
 
